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 SUMMARY 
Post-transcriptional regulation of gene expression takes place at multiple levels between 
transcription and decay of the mRNA. RNA-binding proteins (RBPs) play a key role in 
orchestrating splicing, export, stability, localization and translation of mRNAs. FUS, EWSR1 and 
TAF15 constitute the FET protein family which participates in multiple levels of cellular function. 
FET proteins have been implicated to function in various cellular processes including transcription, 
pre-mRNA splicing and miRNA processing. Translocations and mutations in FET proteins lead to 
diverse pathologies. FUS is involved in neurodegenerative diseases like frontotemporal lobar 
degeneration (FTLD) and amyotrophic lateral sclerosis (ALS).  
In this study, Photoactivatable-Ribonucleoside-Enhanced Crosslinking and Immunoprecipitation 
(PAR-CLIP) was used to determine RNA-targets and binding sites of FUS, EWSR1 and TAF15, an 
ALS-causing FUS mutant and another ALS-related protein, TARDBP. The identified binding sites 
of FET proteins were mainly intronic, supporting the involvement of FUS and EWSR1 in splicing, 
which was validated by FET protein knockdown. Comparison of FUS and TARDBP RNA targets 
revealed that ubiquitin-proteasome related gene categories were overrepresented, further illustrating 
that aberrations in protein degradation are implicated in the pathogenesis of ALS. In addition, it was 
shown that FUS and TAF15 proteins preferentially bind UAC rich, single-stranded RNA sequences. 
mRNA sequencing after FUS, EWSR1 and TAF15 depletion in HEK293 cells revealed a stabilizing 
effect on their targets.  
Interestingly, FET proteins also seem to influence transcription by interaction with promoter-
associated noncoding RNAs. 
In summary, we identified the RNA-targets and binding sites of all human FET proteins in 
comparison with an ALS-causing FUS mutant and TARDBP. Functional studies revealed an 
involvement of FET proteins in mRNA stabilization, splicing and transcriptional regulation.  
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 ZUSAMMENFASSUNG 
RNA-bindende Proteine (RBPs) spielen eine zentrale Rolle in der posttranskriptionellen Kontrolle 
von mRNAs, die zwischen Transkription und Abbau von mRNAs stattfindet. RBPs beeinflussen 
Spleißen, Export, Stabilität, Lokalisierung und Translation von mRNAs. FUS, EWSR1 und TAF15 
gehören zu der Familie der FET Proteine. Diese wirken an verschiedenen zellulären Prozessen wie 
Transkription, Spleißen und der Prozessierung von miRNAs mit. Translokationen und Mutationen 
der FET Proteine führen zu verschiedenen Krankheiten. FUS spielt eine Rolle bei den 
neurodegenerativen Krankheiten frontotemporale Lobärdegeneration (FTLD) und amyotrophe 
Lateralsklerose (ALS).   
In dieser Arbeit wurde die mithilfe von photoaktivierbaren Ribonukleotiden UV-Licht induzierte 
Quervernetzung und Immunpräzipitation (PAR-CLIP) Methode genutzt, um die RNA-Bindestellen 
von FUS, EWSR1 und TAF15, einer ALS-verursachenden FUS Mutante und einem anderen, mit 
ALS in Verbindung stehenden Protein, TARDBP, zu bestimmen. Die RNA-Bindestellen der FET-
Proteine lagen größtenteils in Introns. Passend dazu konnte durch knockdown der FET Proteine eine 
Rolle von FUS und EWSR1 im Spleißen von mRNAs validiert werden. Dem Ubiquitin-Proteasom-
System zugehörige RNAs waren unter den sowohl von FUS als auch TARDBP gebundenen 
mRNAs überrepräsentiert. Dies bestätigt die Annahme, dass Störungen in der Proteindegradation  
die ALS-Pathogenese beeinflussen. Zusätzlich konnte gezeigt werden, dass FUS und TAF15 
bevorzugt UAC-reiche, einzelsträngige RNA-Sequenzen binden. Sequenzierung von mRNAs nach 
Depletion von FUS, EWSR1 und TAF15 in HEK293-Zellen zeigte einen stabilisierenden Effekt der 
FET-Proteine auf gebundene mRNAs. Desweiteren scheinen die FET Proteine durch Interaktion mit 
Promotor-assoziierten, nicht-kodierenden RNAs die Transkription zu beeinflussen.  
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Introduction 
1.  Introduction 
1.1  Posttranscriptional gene regulation by RNA-binding proteins 
In eukaryotes, transcription and translation are locally separated in the nucleus and cytoplasm. 
Therefore, pre-mRNAs can undergo extensive post-transcriptional processing to achieve more 
diversity and introduce additional layers of gene regulation. Pre-mRNA processing includes 
splicing, capping, polyadenylation and editing of protein-coding transcripts. Consequently, post-
transcriptional regulation of gene expression takes place at multiple levels between transcription 
and decay. Besides small non-coding RNAs, RNA-binding proteins (RBPs) play a key role in 
post-transcriptional control of mRNAs by orchestrating splicing, export, stability, localization 
and translation of mRNAs (Fig.1).   
The human genome encodes around 600 proteins with RNA-binding domains (de Lima Morais 
et al. 2011; Ray et al. 2013), whereas the number of known RNA-binding domains is relatively 
small. Experimentally, two recent studies expanded this set to about 1100 mRNA-binding 
proteins (Baltz et al. 2012; Castello et al. 2012). Often RBPs contain more than one RNA-
binding domain which in combination ensure specificity and affinity of binding (Lunde et al. 
2007). In addition, several domains allow protein-protein interactions to form ribonucleoprotein 
particles (RNPs). In combination with additional functional domains the diversity of RBPs 
increases and allows a single RBP to bind multiple targets. 
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Fig. 1: Posttranscriptional gene regulation. 
In eukaryotic cells, mRNAs undergo several steps of regulation from transcription to translation. The coordination 
of multiple mRNAs is regulated by RNA-binding proteins and small non-coding RNAs at different levels. miRNAs, 
microRNAs; siRNAs, small interfering RNAs. Modified from (Keene 2007). 
1.2  Structure and functions of RNA-binding proteins 
RBPs are often composed of multiple copies of a just few functional domains. Combination of 
different domains creates versatility in RNA binding with high affinity and high specificity. This 
modular structure of RBPs gives rise to a large functional repertoire of these proteins (Burd and 
Dreyfuss 1994). Further advantages of the modular protein structure are that these proteins can 
bind longer stretches of nucleic acids, sequences which are separated by nucleotides and 
sequences from different RNA molecules. This section will briefly summarize the most common 
RNA-binding domains and functions (Fig.2). 
1.2.1  The RNA-recognition motif  
One of the most abundant and best characterized RNA-binding domains in eukaryotes is the 
RNA-recognition motif (RRM). It is composed of 80-90 amino acids that form a four-stranded ß-
sheet against two α-helices (Oubridge et al. 1994). RNA recognition usually occurs on the 
surface of the ß-sheet. A single RRM can recognize two (Mazza et al. 2002) to eight nucleotides 
(Price et al. 1998) but multiple domains are often needed to define sequence specificity because 
the number of recognized nucleotides by a single RRM is often too small to define a unique 
binding sequence (Auweter et al. 2006). RRM-domain-containing proteins are involved in many 
cellular functions, for instance mRNA and ribosomal RNA processing, splicing, translation, RNA 
export and stability (Dreyfuss et al. 2002). One example is the poly(A)-binding protein which 
regulates translation initiation (Kahvejian et al. 2005). 
1.2.2  The K-homology domain 
The K-homology domain (KH domain) was initially identified as a repeated sequence in the 
heterogenous nuclear ribonucleoprotein (hnRNP) K. The KH domain is composed of an 
evolutionary conserved sequence of around 70 amino acids which form a three stranded ß-sheet 
packed against three α-helices (Grishin 2001). It can bind single-stranded (ss) DNA as well as 
ssRNA (Backe et al. 2005) recognizing four nucleotide long sequences.  
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KH domains are found in RBPs with different functions including splicing, transcriptional 
regulation and translational control like the neuronal splicing factor Nova-1 (Lewis et al. 1999). 
1.2.3  The Zinc finger domain 
Zinc finger (ZF) were initially described as  DNA-binding domains (Miller et al. 1985) but more 
recently, it was shown that ZF can also bind to RNA, protein and lipids (Matthews and Sunde 
2002; Hall 2005; Gamsjaeger et al. 2007). A classical ZF domain is around 30 amino acids long 
which form a ββα structure held together by a Zn2+ ion. They are further classified depending on 
the amino acids that are interacting with this ion and are generally present in multiple repeats per 
protein. The different classes of ZFs differ largely in function as they mediate the interaction of 
proteins with other biomolecules. These classes have a variety of different roles within the cell 
like transcriptional regulation, mRNA processing and ubiquitination (Aasland et al. 1995; Lu et 
al. 2002; Loughlin et al. 2009). 
1.2.4  The double-stranded RNA-binding motif 
In contrast to the RNA-binding domains described above, double-stranded RNA-binding motifs 
(dsRBMs) were first described to recognize RNA structure rather than RNA sequence (Stefl et al. 
2005). They are 70-90 amino acid long sequences which exhibit a conserved αββα protein 
topology. DsRBMs are often found in multiple repeats and are involved in a variety of functions 
within the cell like RNP localization, RNA interference, RNA processing, RNA localisation, 
RNA editing and translational control (Chang and Ramos 2005). Recently, the structure of 
ADAR dsRBMs in complex with RNA also revealed sequence specificity in dsRNA-binding 
(Stefl et al. 2010). 
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Fig. 2: Structures of RNA-binding domains in complex with RNA. 
(A) Structure of the N-terminal RRM of human U1A bound to RNA. (B) The KH3 domain of Nova-2 bound to 5'-
AUCAC-3'. (C) The yeast Rnt1 dsRBD bound to an RNA helix capped by an AGNN tetraloop. (D) The two zinc 
fingers of TIS11d bound to an AU-rich RNA element. In all panels, the RNA backbone is represented with an orange 
ribbon, -helices are in red and -sheets are in yellow; the zinc atom in the TIS11d structure is in magenta. 
Modified from (Lunde et al. 2007). 
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1.3  The FET protein family 
Fused in sarcoma (FUS), Ewing sarcoma breakpoint region 1 (EWSR1) and TATA-binding 
protein-associated factor 15 (TAF15) constitute a family of RNA/DNA-binding proteins, known 
as FET proteins (Bertolotti et al. 1996). FET proteins are highly expressed in almost all human 
fetal and adult tissues and are predominantly located in the nucleus, although they are able to 
shuttle between the nucleus and cytoplasm (Andersson et al. 2008). 
1.3.1  Structure and binding preferences of the FET proteins 
The FET proteins are structurally very similar and composed of several domains (Fig.3). The N-
terminal end contains a serine-tyrosine-glycine-glutamine-rich domain (SYGQ-domain), which 
can serve as transcriptional activation domain when fused to other transcription factors in 
cancer associated translocations (Zinszner et al. 1994; Bertolotti et al. 1999). At their C-termini, 
FET proteins harbour domains that are implicated in nucleic acid binding. The most conserved 
region is an RRM (Tan and Manley 2009), which is flanked by several arginine-glycine-
glycine-rich domains (RGG) and a RanBP2-type ZF. RanBP2-type ZFs were shown to bind 
single-stranded RNA with preference to GGU-containing motifs (Loughlin et al. 2009; Nguyen 
et al. 2011). FET proteins have been reported to bind both RNA as well as ss and dsDNA 
(Bertolotti et al. 1996; Hackl and Luhrmann 1996). Recently, a study by Takahama et al. 
showed that the RGG-rich domain of FUS forms a ternary complex with the human telomere G-
quadruplex DNA and telomeric repeat-containing RNA in vitro (Takahama et al. 2013). This 
observation indicates that the RGG-rich domain might be also responsible for the DNA-binding 
properties of the FET proteins. The region with the highest degree of sequence identity between 
all three FET family members is the RRM (Tan and Manley 2009). It folds into a secondary 
structure which might be involved in sequence specific RNA binding (Burd and Dreyfuss 1994; 
Hackl and Luhrmann 1996). Together with the RGG-rich domains, these regions are essential 
for the RNA-binding specificity of the FET proteins. Sequence-specific binding was reported 
for both FUS and EWSR1, indicating that the proteins interact with polyU and polyG stretches 
(Ohno et al. 1994). Furthermore, it was shown that FUS binds specifically to a GGUG motif 
(Lerga et al. 2001) and AU-rich stem-loop structures (Hoell et al. 2011). The RNA-binding 
specificity of TAF15 remains elusive. 
At their very C-terminal end all three FET proteins harbour a nuclear localization signal (NLS) 
which mediates transport of the proteins into the nucleus (Zakaryan and Gehring 2006; 
Dormann et al. 2010; Marko et al. 2012).  
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Nuclear import of the FET proteins is mediated by Transportin 1 and 2 (Dormann et al. 2010) 
whereas nuclear import of EWSR1 is also dependent on the phosphorylation state of the C-
terminus (Leemann-Zakaryan et al. 2011). Taken together, the domain composition suggests 
diverse functions of the FET proteins (see next section). 
 
 
 
 
Fig. 3: Domain structure of the FET protein family and TARDBP. 
FUS, EWSR1 and TAF15 share the same domain structure. The N-terminal end consists of a SYGQ-rich domain. 
The C-terminus is composed of a G-rich domain, a RRM domain, a ZF domain flanked by two RGG boxes and a 
nuclear localization signal. The unrelated TARDBP consists of an N-terminal nuclear localizations signal, two RRM 
domains and a C-terminal G-rich domain. 
 
 
1.3.2  Functions of the FET proteins 
The FET proteins seem to be implicated in various cellular processes. The next section will give 
an overview of the current state of knowledge about functions of FUS, EWSR1 and TAF15. 
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1.3.2.1  Transcriptional regulation 
Several lines of evidence suggest an involvement of FET proteins in transcription. FUS, 
EWSR1 and TAF15 were found to interact with distinct subpopulations of the RNA Polymerase 
II ( RNA Pol II) associated complex TFIID as well as RNA Pol II subunit hRPB3 (Bertolotti et 
al. 1996; Hoffmann and Roeder 1996; Bertolotti et al. 1998). Transcription factor II D (TFIID) 
is composed of the TATA box binding protein (TBP) and TBP-associated factors (TAF(II)s) and 
is involved in initiation and elongation of transcription (Workman and Roeder 1987).  In 
addition, FUS and EWSR1 were reported to interact with various transcription factors like 
POU4F1 (Thomas and Latchman 2002) and OCT4 (Lee et al. 2005). These observations 
suggest an involvement of FUS and EWSR1 in transcriptional regulation. Moreover, FET 
proteins function in a so far unique case of transcriptional regulation. FUS, EWSR1 and TAF15 
bind to non-coding RNAs (ncRNA) derived from the promoter of the cyclin D1 gene upon 
DNA damage, which is transcriptionally repressed in cis through inhibition of the p300 histone 
acetyltransferase by a FET-ncRNA ribonucleoprotein complex (Wang et al. 2008). Besides their 
role in RNA Pol II mediated transcription, recent findings also suggest FUS repressing RNA Pol 
III transcription of small untranslated RNAs (Tan and Manley 2010). 
 
1.3.2.2  Splicing 
Many studies associated FET proteins with pre-mRNA splicing as they were identified as part 
of the spliceosome (Rappsilber et al. 2002). Originally, FUS was identified as the hnRNP P2 
belonging to a group of proteins involved in pre-mRNA-processing (Calvio et al. 1995). 
Furthermore, FUS and EWSR1 are interacting with multiple splicing factors like YBX1 
(Chansky et al. 2001) and serine-arginine proteins such as TASR and SC35 (Yang et al. 1998; 
Yang et al. 2000). In addition, FUS associates with hnRNP A1 and C1/C2 as well as with 
SRm160 and PTB (Lerga et al. 2001; Meissner et al. 2003). Moreover, FUS was found to bind 
to the pre-mRNA 3’ splice site and seemed to promote the usage of distal 5’ splice sites (Wu and 
Green 1997; Hallier et al. 1998). The interaction of FUS with the splicing machinery appears to 
have functional consequences since splicing of pre-mRNAs expressed from several minigenes 
is affected by the FET proteins (Hallier et al. 1998; Chansky et al. 2001; Kino et al. 2011).  
Recently, two studies showed that FUS has an effect on alternative splicing with increased 
binding of FUS to introns around repressed exons using brain from FUS -/- mice and  FUS-
silenced primary cortical neurons, respectively (Ishigaki et al. 2012; Rogelj et al. 2012).  
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Similarly, Paronetto and coworkers could show that depletion of EWSR1 in HeLa cells leads to 
changes in alternative splicing of DNA damage-induced genes (Paronetto et al. 2011). It would 
be conceivable that the FET proteins co-regulate transcription and splicing as they are able to 
bind both RNA Pol II and various splicing factors and since transcription is physically and 
functionally coupled to splicing (Montes et al. 2012). 
1.3.2.3  mRNA transport 
Since the FET proteins can shuttle between the nucleus and cytoplasm (Zinszner et al. 1997) 
they have been also implicated in mRNA transport. FUS is localized in dendrites of mouse 
hippocampal neurons and is transported to spines upon activation of the glutamate receptor 5 
(Fujii et al. 2005). One mRNA that is transported by FUS to dendritic spines is Nd1-L, encoding 
an actin-stabilizing protein which may play a role in the dynamic organization of the actin 
cytoskeleton (Sasagawa et al. 2002; Fujii and Takumi 2005). Whether EWSR1 and TAF15 also 
play a role in RNA transport and cytoskeleton stabilization has not been investigated yet. FUS 
and TAF15 are also implicated in regulation of localized protein synthesis since they are 
accumulating together with other RBPs in spreading initiation centers of adhering cells (de 
Hoog et al. 2004; Andersson et al. 2008). 
 
1.3.2.4  miRNA biogenesis 
Moreover, FET proteins seem to participate in the regulation of miRNA processing as they were 
identified as part of the large Drosha complex (Gregory et al. 2004). For FUS and EWSR1, 
direct interaction with Drosha was demonstrated recently (Morlando et al. 2012; Sohn et al. 
2012). Drosha is a nuclear RNase III enzyme which processes pri-miRNAs to pre-miRNAs as 
part of the microprocessor complex. Besides Drosha, also DGCR8 belongs to the 
microprocessor complex (Lee et al. 2003). DGCR8 contains an RNA-binding domain and is 
thought to bind and recognize pri-miRNAs for processing by Drosha (Yeom et al. 2006). FUS 
was identified as one of DGCR8-associated proteins (Shiohama et al. 2007).  
In addition, FUS regulates miRNA biogenesis by binding specific pri-miRNAs involved in 
neuronal function and differentiation (Morlando et al. 2012). EWSR1 might directly or 
indirectly function in the maturation of let-7g as depletion of EWSR1 lead to an accumulation 
of pre-let-7g but downregulation of mature let-7g (Sohn et al. 2012).  
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A recent study by Ballarino and colleagues could show that also TAF15 is involved in miRNA 
mediated regulation of CDKN1A expression which is a key regulator of cell cycle and cell death 
(Ballarino et al. 2012). Hence, the FET proteins might also be important regulators of miRNA 
maturation but the exact mechanism remains elusive.  
 
1.3.2.5   Genome surveillance 
Additionally, the FET proteins have been associated with genomic surveillance and DNA repair. 
FUS knockout mice show male sterility and high genomic instability (Kuroda et al. 2000). FUS 
knockout mice as well as EWSR1 deficient mice have a defective B-cell development and show 
enhanced sensitivity to radiation (Hicks et al. 2000; Li et al. 2007). Furthermore, inactivation of 
EWSR1 in embryonic fibroblasts resulted in reduced meiotic recombination and premature 
cellular senescence (Li et al. 2007).  Together with the ability of all three FET proteins to 
mediate pairing of homologous DNA ends, this suggests a role in DNA repair (Baechtold et al. 
1999; Bertrand et al. 1999; Guipaud et al. 2006). This hypothesis is strengthened by the 
interaction of EWSR1 with the BRCA1-associated ring finger domain protein BARD1 (Spahn 
et al. 2002). BARD1 binds to the breast cancer susceptibility gene BRCA1 that provides a 
platform for interactions with proteins involved in DNA repair and checkpoint control 
(Venkitaraman 2001). 
 
Taken together, the FET family are involved in multiple cellular functions like transcription, 
splicing, RNA transport, miRNA biogenesis and DNA repair suggesting a possible role as 
master regulators in the cell. 
 
1.3.3  FET proteins and their involvement in diseases 
Recent studies revealed an association of FET proteins with neurological disorders. Mutations in 
the C-terminus of FUS can lead to amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative 
disease characterized by a late-onset premature loss of upper and lower motor neurons in the 
cerebral cortex, brainstem and spinal cord (Kwiatkowski et al. 2009; Vance et al. 2009). This 
leads to a progressive skeletal muscle atrophy, causing death within 2 to 5 years due to 
respiratory failure (Kiernan et al. 2011). About 10% of all ALS cases are dominantly inherited, 
whereas the remaining cases are sporadic.  
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Besides mutations in other genes like superoxide dismutase 1 (SOD1) and C9orf72 about 4% of 
all familial ALS cases and rare sporadic cases are caused by mutations in the FUS gene. The 
mutant FUS protein is mislocalized to the cytoplasm accumulating in ubiquitin-positive inclusion 
bodies in neurons and glial cells of brain and spinal cord of ALS patients (Kwiatkowski et al. 
2009). Most of the FUS mutations causing ALS are located at the C-terminus where the NLS is 
located, leading to disrupted Transportin binding and disturbed nuclear import of the protein 
(Dormann et al. 2010; Ito et al. 2011). The mutated protein is recruited into stress granules 
(Bosco et al. 2010), cytosolic structures composed of temporally stored mRNAs and associated 
RBPs, which form upon environmental stresses like oxidative stress or heat shock (Anderson and 
Kedersha 2008).  
A study by Daigle and coworkers showed that incorporation into stress granules of the FUS 
mutant protein is dependent on the RNA-binding ability of the protein. Furthermore, RNA-
binding of FUS regulates cytoplasmic mislocalization and neurodegeneration since RNA-
binding-incompetent FUS mutants block the neurodegenerative phenotype in a Drosophila ALS 
model and neuronal cell line (Daigle et al. 2013).  In contrast, a recent study by Shelkovnikova 
and colleagues revealed that FUS aggregation is sufficient to cause an ALS-like phenotype in 
transgenic mice (Shelkovnikova et al. 2013). Expression of a FUS variant lacking the RNA-
binding domain and the NLS in transgenic mice causes severe damage of motor neurons 
suggesting that aggregation of FUS protein can by itself trigger neuroinflammation independent 
of its roles in RNA metabolism. 
Recent reports also implicate EWSR1 and TAF15 mutations in ALS (Couthouis et al. 2011; 
Ticozzi et al. 2011; Couthouis et al. 2012). Similar to ALS, FUS-containing inclusion bodies 
were also found in sub-population of patients with frontotemporal lobar degeneration (FTLD), 
which is characterized by degeneration of frontal and temporal cortical neurons, confirming the 
long-standing thought that the two diseases are related (Neumann et al. 2009).  
Nevertheless, the pathology of FTLD-FUS is slightly different since all three FET proteins co-
localize in pathological inclusion bodies whereas in ALS-FUS patients no co-deposition of 
EWSR1 and TAF15 in FUS-positive inclusions was observed (Neumann et al. 2011). 
Interestingly, mutations in a second RNA/DNA-binding protein, TARDBP/TDP-43, were also 
discovered in patients with ALS and FTLD. TARDBP is structurally unrelated to FET proteins 
(Fig. 3) and likewise ubiquitin-positive cytoplasmic inclusions containing TARDBP are observed 
in disease-affected tissues (Neumann et al. 2006).  
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In contrast to mutations in FUS, most of the identified ALS causing mutations in TARDBP are 
clustered in the C-terminal glycine-rich region which mediates interaction with other hnRNP 
proteins regulating splicing of pre-mRNAs (Buratti et al. 2005). Unlike FUS, none of the 
identified mutations so far are located in the NLS of TARDBP indicating no effect on nuclear 
transport of the protein.  
Interestingly, FUS and TARDBP were found in direct interaction as part of a biochemical 
complex regulating histone deacetylase 6 (HDAC6) mRNA levels (Kim et al. 2010). ALS-
causing mutations of TARDBP also increase stability of the mutant protein and promote 
complexes with FUS (Ling et al. 2010). These genetic findings and the common pathology 
indicate that FUS and TARDBP proteins abnormally aggregate in ALS and FTLD, and suggest 
similar molecular mechanisms aberrantly regulated at the post-transcriptional level as potential 
pathogenic clues, although the primary or secondary role of each of these events in triggering 
motor neuron degeneration still need to be determined. 
In addition, genetic aberrations in FET proteins are also associated with several other human 
diseases. FUS and EWSR1 were initially discovered to be chromosomally translocated in 
sarcomas (Delattre et al. 1992; Crozat et al. 1993), which are aggressive cancers of the 
supportive and connective tissue in the human body. Chromosomal translocation results in the 
fusion of the N-terminal transcriptional activator domain of the FET proteins to the DNA binding 
domain of various transcription factors. This leads to aberrant transcriptional activation under the 
control of the FET protein promoter. FUS and EWSR1 were both found to be fused to the 
transcription factors CHOP and ERG, for example, leading to the development of myxoid 
liposarcoma and Ewing’s sarcoma family of tumours, respectively (Crozat et al. 1993; Rabbitts 
et al. 1993; Zucman et al. 1993). Furthermore, cancer associated fusion of TAF15 to ZNF384 has 
been observed in acute leukaemia (Martini et al. 2002). Translocation affects only one allele 
therefore tumour cells express both full-length FET proteins and fusion protein. It was shown 
that both protein forms are strongly expressed in tumour cells (Spitzer et al. 2011), so it is rather 
a gain-of-function of the fusion protein which leads to deregulated target expression and an 
altered differentiation pattern of the cells (Martini et al. 2002).  
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1.4  Outline and objectives of the thesis 
RBPs play a key role in post-transcriptional control of mRNAs. Post-transcriptional regulation of 
gene expression takes place at multiple levels during the lifecycle of an mRNA. RBPs 
orchestrate splicing, export, editing, stability, localization and translation of mRNAs. 
FUS, EWSR1 and TAF15 constitute the FET family of proteins which are involved in several 
steps of post-transcriptional regulation. In this thesis the diverse functions of all three members 
of the FET family were systematically studied in HEK293 cells as a model cell line. 
Principal aim of this work was to characterize the regulatory functions and mechanisms on the 
transcriptional and post-transcriptional level of the FET family by using several systematic high- 
throughput approaches (Fig.4): 
• A prerequisite for understanding the function of RBPs is a comprehensive identification 
of RBP binding sites. Therefore, PAR-CLIP methodology was used to define the target 
transcripts, binding sites and possible binding motifs of FUS, EWSR1 and TAF15 in 
comparison with an ALS causing FUS truncation mutant (FUS R495X) and TARDBP, 
another protein involved in ALS. 
• Subsequently, the next aim was to identify at which step of gene expression these targets 
are regulated by siRNA mediated knockdown of all three FET proteins in HEK293 cells. 
Correlation of changes after FET protein depletion in 
o abundance and splicing of mRNAs was determined by mRNA sequencing 
(mRNA-Seq) 
o miRNA expression was examined by small RNA sequencing (small RNA-Seq) 
o protein abundance was analyzed using stable isotope labeling with amino acids in 
cell culture (SILAC)  
o transcription was investigated by chromatin immunoprepecipitation followed by 
quantitative polymerase chain reaction (ChIP-qPCR) 
 
By relating the protein-RNA interaction maps to RNA sequencing data and the proteomic analysis 
of FET-depleted cells, functions and regulatory mechanisms of each FET family member on the 
post-transcriptional level can be deduced. Comprehensive protein-RNA interaction maps of the 
FET proteins are crucial to identify common or non-redundant regulatory functions. 
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By using several systematic high-throughput approaches for all three FET family members and 
TARDBP together with a disease related FUS mutant in one cell line it is feasible to correlate the 
genomic, transcriptomic and proteomic data sets.  
Previous studies only indentified the RNA targets of FUS and TARDBP individually but not in 
comparison with EWSR1 and TAF15 (Polymenidou et al. 2011; Tollervey et al. 2011; Lagier-
Tourenne et al. 2012; Rogelj et al. 2012). Only one recent study defined the global RNA targets of 
all three FET proteins in comparison with two ALS-causing FUS mutants (Hoell et al. 2011). 
Despite several biochemical studies investigating the function of FET proteins in various nuclear 
processes, the impact of FET proteins on RNA binding with respect to the development of ALS 
have been unexplained. Comparison of FET protein data with TARDBP and the FUS mutant data 
sets will likely shed more light into reasons and development for ALS which could be based on 
differences in RNA binding.  
 
 
 
 
Fig. 4: Overview of the project. 
Outline of the overall experimental approach. PAR-CLIP of FUS, EWSR1 and TAF15 were done in HEK293 cells. 
Together with siRNA mediated knockdown of the FET proteins followed by mRNA sequencing, small RNA 
sequencing, mass spectrometry and chromatin immunoprecipitation  (ChIP) followed by qPCR changes in relative 
RNA and protein abundance of FET target mRNAs were elucidated. 
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2. Materials and methods 
2.1 Cell lines and culture conditions 
2.1.1 Cloning 
Plasmids pENTR4 FUS, FUSR495X, EWSR1, TAF15 and TARDBP and were generated by 
polymerase chain reaction (PCR) amplification of the respective coding sequences (Tab.1) using 
HEK293 genomic DNA as a template (primers listed in 2.13.1). PCR was followed by restriction 
digest with SalI and NotI and ligation into pENTR4 (Invitrogen, UK). pENTR4 FUS, FUS R495X, 
EWSR1, TAF15 and TARDBP were recombined into pFRT/TO/FLAG/HA-DEST destination 
vector (Invitrogen, UK) using GATEWAY LR recombinase (Invitrogen,UK) according to the 
manufacturer’s protocol to allow for doxycycline-inducible expression of stably transfected 
FLAG/HA-tagged protein in Flp-In T-REx HEK293 cells (Invitrogen, UK). 
 
Tab. 1: NCBI Reference Sequence numbers of cloned coding sequences 
Gene NCBI Reference Sequence 
FUS NM_004960.3 
EWSR1 NM_013986.3  
TAF15 NM_139215.2 
TARDBP NM_007375.3 
 
2.1.2 Cell lines and culture conditions 
HEK293 T-REx Flp-In cells (Life Technologies, UK) were cultivated at 37°C and 5% CO2 in 
DMEM high glucose (Life Technologies) with 10% (v/v) fetal bovine serum (Life Technologies, 
UK), 1% (v/v) 2mM L-glutamine (Life Technologies, UK), 1% (v/v) 10,000 U/ml 
penicillin/10,000 µg/ml streptomycin (Life Technologies, UK), 100 µg/ml zeocin (Invivogen, 
USA) and 15 µg/ml blasticidin (Invivogen, USA). SILAC medium was prepared as described 
previously (Ong & Mann, 2006).  
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Briefly, DMEM Glutamax lacking arginine and lysine (PAA, Austria) was supplemented with 10% 
dialyzed FBS (Sigma-Aldrich, Germany) and 2 mM L-glutamine (PAA, Austria). Amino acids (84 
mg/l 13C615N4 L-arginine plus 146 mg/l 13C615N2 L-lysine or 84 mg/l 13C6-L-arginine plus 146 mg/l 
D4-L-lysine) were added to obtain „heavy“ and „medium-heavy“ medium, respectively. The 
corresponding non-labeled amino acids were used to prepare non-labeled “light” medium. All 
amino acids were purchased from Sigma-Aldrich (Germany). 
HEK293 T-REx Flp-In cells stably expressing FLAG/HA-tagged proteins were generated by co-
transfection with a 1:9 ratio of pFRT/TO/FLAG/HA constructs with pOG44 (Life Technologies, 
UK) using Lipofectamine 2000 (Life Technologies, UK). Cells were selected by exchanging 
zeocin with 100 mg/ml hygromycin (Sigma-Aldrich, Germany). 
 
2.2 siRNA transfection  
For knockdown experiments HEK293 T-REx Flp-In cells were grown in light SILAC medium. 
siRNA transfections of cells were performed in 6-well format using Lipofectamine RNAiMAX 
(Life Technologies, UK) as described by the manufacturer. One day before transfection 5x105 cells 
were seeded. Transfections were carried out in SILAC-DMEM supplemented with 2 mM L-
glutamine as transfection medium and 150 pmol siRNA and 7.5 µl Lipofectamine RNAiMAX for 
each transfection. Control transfections (mock) contained only the transfection reagent. Cells were 
harvested four days after transfection. Knockdown efficiency of proteins was checked by Western 
blot analysis and quantitative real-time polymerase chain reaction (qRT-PCR).  
2.3 RNA extraction  
Total RNA was extracted using the miRNAeasy Mini kit (Qiagen, Germany) as described by the 
manufacturer. RNA concentration and quality was assessed using a NanoDrop ND-1000 UV-VIS 
Spectrophotometer (Thermo Fisher Scientific, USA). 
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2.4 Poly(A) RNA isolation 
Poly(A) mRNA was purified from 1 μg of total RNA using the Dynabeads mRNA Purification Kit (Life 
Technologies, UK) according to the manufacturer’s protocol. The eluate was hybridized to the same 
beads for the second extraction step. Depletion of ribosomal RNAs was validated by capillary gel 
electrophoresis on a Bioanalyzer (Agilent, USA). Poly(A) RNA was subsequently processed for 
sequencing (see below). 
2.5 Transcriptome sequencing 
The poly(A)+ mRNA fraction was used for the sequencing library preparation according to the 
NEBNext mRNA Sample Prep kit (NEB, USA) instructions, with modifications. The mRNA was 
eluted from the beads with 17 µl of 10 mM Tris-HCl (pH 7.5), combined with 4 µl of 5x 
fragmentation buffer, incubated for exactly 3.5 min at 94ºC and placed on ice. This procedure yields 
RNA fragments ranging from 60 to 200 nt. After fragmentation, the RNA was purified using 
Agencourt RNAClean XP beads (Beckman Coulter Genomics, USA) according to manufacturer's 
protocol. Complementary DNA (cDNA) synthesis, end repair, addition of A overhangs and ligation 
of the adapters were performed as described in the NEBNext mRNA Sample Prep kit, each step 
followed by purification on Agencourt AMPure XP beads (Beckman Coulter Genomics, USA). The 
library was then PCR-amplified using Phusion polymerase (Thermo Fisher Scientific, USA) for 15 
cycles of 10 s at 98ºC, 30 s at 65ºC and 30 s at 72ºC. After purification on Agencourt AMPure XP 
beads (Beckman Coulter Genomics, USA), the concentration and quality of the library were 
assessed by gelelectrophoresis on the Bioanalyzer using the DNA 1000 kit (both Agilent 
Technologies, USA). dsDNA libraries subsequently processed for sequencing using the Genomic 
DNA Sample Prep Kit (Illumina, USA) according to the manufacturer’s protocol. Libraries were 
sequenced on Illumina Genome Analyzer GAII or Illumina HiSeq (Illumina, USA) using the 2x76 
bp paired-end protocol. 
2.6 Small RNA sequencing 
Small RNAs of knockdown cells were isolated from 10 µg total RNA using the FlashPage Gel 
system (Life Technologies, UK) and sequenced using the small RNA cloning protocol (Hafner et 
al., 2008) with barcoded pre-adenylated 3’adapters (2.13.3.2). 
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2.7 Quantitative Real-Time - Polymerase Chain Reaction (qRT-PCR) 
Single stranded cDNAs were synthesized from total RNA with an oligo-d(T)18 primer or random 
hexamer primers using Superscript III Reverse Transcriptase (Life Technologies, UK) according to 
the manufacturer’s instructions. 
RT-PCR was performed using Power SYBR Green PCR master mix (Applied Biosystem, USA) on 
the StepOne Real-Time PCR System (Applied Biosystem, USA) for 30 cycles of 15 s at 94°C, 15 s 
at 60°C, and 20 s at 72°C. 
For quantification of miRNA levels, TaqMan Micro RNA Assays from Applied Biosystems 
(RNU24, RNU6B,  hsa-miR-34a, has-miR-374b, hsa-miR-92a, hsa-miR-10a, has-miR-148a, has-
miR-19a) and 2x TaqMan PCR Mastermix (Applied Biosystems, USA) were used according to 
manufacturer’s instructions.  
2.8 Quantification of alternative exon inclusion 
Two µg of total RNA was reverse transcribed with an oligo-d(T)18 primer using Superscript III 
Reverse Transcriptase (Life Technologies, UK) according to the manufacturer’s instructions. PCR 
amplification was performed using the KOD Hot Start DNA Polymerase kit (Novagen, Germany), 
0.3 µM of each of the forward and reverse primers, and 2µl of cDNA (10% of the reverse 
transcription reaction) for 27 - 30 cycles of 20 s at 95 ºC, 15 s at 60 ºC, and 15 s at 70ºC. 
PCR products were purified using PCR purification kit (Qiagen, Germany) and resolved on 2 % 
TBE-agarose gels. In parallel, PCR products were analyzed by the BioAnalyzer DNA 1000 Assay 
(Agilent technologies, USA). PSI (percent spliced in) values were calculated as the molar ratio of 
the peak corresponding to the exon containing isoform and the sum of the peaks representing both 
isoforms. 
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2.9 Labeling of proteins, sample preparation and measurement by mass 
spectrometry 
Protein extraction, sample preparation and analysis by liquid chromatography tandem mass 
spectrometry (LC-MS/MS) was conducted by Dr. Guido Mastrobuoni, member of the Integrative 
Proteomics and Metabolomics group at the Berlin Institute for Medical Systems Biology at the Max- 
Delbrück Center for Molecular Medicine (Robert-Rössle Str. 10, D-13125 Berlin, Germany)  
Prior transfection cells were grown at least two weeks in light SILAC medium. Transfection was 
performed as described (see 2.2). 29 hours after transfection, siRNA and mock-transfected cells 
were transferred to medium-heavy and heavy SILAC medium, respectively. After 24 hours of 
labeling, cells were harvested and equal numbers of siRNA- and mock-transfected cells were 
pooled. Proteins were extracted, digested and analyzed by liquid chromatography tandem mass 
spectrometry (LC-MS/MS) on a high-resolution instrument (LTQ-Orbitrap Velos, Thermo 
Scientific, USA). Raw data were analyzed using the MaxQuant proteomics pipeline (v1.2.2.5). 
2.10 Western blotting 
Cells were collected and lysed in 3 volumes of NP40 lysis buffer (50 mM HEPES-K pH 7.5, 150 
mM KCl, 2 mM EDTA, 0.5% (v/v) NP-40, 0.5 mM DTT, complete EDTA-free protease inhibitor 
cocktail (Roche, Switzerland)). Protein concentration was determined using Bradford reagent 
(Thermo Scientific, USA). Proteins were subjected to SDS-PAGE and transferred to nitrocellulose 
using semi-dry blotting apparatus (Bio-Rad, USA). Membranes were blocked for 2 h at RT with 
5% (w/v) non-fat milk in TBST and incubated with primary antibodies at 4°C over night. HRP-
conjugated secondary antibodies (Dako, Denmark) were incubated for 1 h at room temperature. 
Bands were visualized with Amersham ECL Western Blotting Detection Reagents (GE Healthcare, 
UK) on a Fujifilm LAS-4000 luminescent image analyzer (GE Healthcare, UK). Primary 
antibodies used were anti-FUS (Abcam, ab23439) 1:1000 diluted, anti-EWSR1 (Abcam, ab81971) 
1:500 diluted, anti-TAF15 (Abcam, ab69581) 1:500 diluted, anti-TARDBP (Abcam, ab57105) 
1:500 diluted, anti-HA (Covance, MMS-101P) 1:1000 diluted and anti-Tubulin (Sigma, T8328) 
1:3000 diluted. Secondary antibodies used were anti-rabbit HRP (Dako, P0048) 1:2000 diluted, 
anti-mouse HRP (Dako, P0447) 1:1000 diluted and anti-goat HRP (Dako, P0449) 1:1000 diluted. 
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2.11 PAR-CLIP 
The PAR-CLIP procedure was performed as published (Hafner et al. 2010) with the following 
modifications. 
2.11.1 Labeling of cells with photoactivatable ribonucleosides 
HEK293 T-REx Flp-In cells (Life technologies, UK) stably expressing FLAG/HA-FUS, FUS 
R495X, EWSR1, TAF15, TARDBP and TARDBP M337V were grown in light SILAC medium 
supplemented with 100 µM 4-thiouridine (4SU) (ChemGenes, USA) or 6-thioguanosine (6SG) 
(Sigma-Aldrich, Germany) to label long-lived transcripts. Expression of recombinant proteins was 
induced by addition of 200 ng/ml doxycycline (SIGMA, USA). After overnight incubation, 100 
µM fresh 4SU or 6SG was added and cells were incubated for additional 2 hours to label short-
lived transcripts.  
2.11.2 UV crosslinking, lysis and immunoprecipitation 
After aspirating the medium, cells were crosslinked on ice using a Stratalinker with customized 365 
nm UV lamps (Stratagene, USA, energy settings 150 mJ/cm2). Cells were harvested in cold PBS, 
pelleted by centrifugation and lysed in 3 volumes of NP40 lysis buffer. The cleared cell lysate was 
partially digested with 1 U/µl RNase T1 (Fermentas, Germany) for 15 min at 22°C and FLAG/HA 
tagged proteins were immunoprecipitated using anti-FLAG antibody at a final concentration of 0.25 
µg/µl (Sigma, F1804) conjugated to Protein G Dynabeads (Invitrogen, UK). For 1 ml of cell lysate, 
20 µl beads and 5 µg of antibody were used. Bound RNAs were partially digested for 6 min at 22°C 
with 50 U/µl RNase T1 (Fermentas, Germany). Beads were then treated with 0.5 U/µl calf intestinal 
phosphatase (NEB, USA) for 60 min at 37°C to dephosphorylate the RNA. Beads were washed and 
crosslinked RNA was labeled with 0.3 μCi/μl γ-32-P-ATP (Perkin-Elmer, NEG 502A) and 1 U/μl  
T4 PNK (Fermentas, Germany).  
2.11.3 SDS-PAGE and electroelution 
Beads were resuspended in 50 µl 2x SDS-PAGE loading buffer (20% glycerol (v/v), 160 mM Tris-
HCl pH 6.8, 4% SDS (w/v), 200 mM DTT, 0.2% bromophenol blue) and RNA-protein complexes 
were separated by SDS-PAGE (NuPAGE Novex 4-20% BT Gel, Invitrogen, UK). The protein-RNA 
complex of the corresponding size was excised and electroeluted from the gel using D-Tube 
Dialyzer Kit MWCO 3.5kDa (Novagen, Germany) for 2h at 100V in SDS running buffer (25mM 
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Tris base, 192 mM glycine, 0.1% SDS). The electroeluate was digested with 2 mg/ml Proteinase K 
(Roche, Switzerland) for 60 min at 55°C. Immunoprecipitated RNA was recovered by phenol-
chloroform extraction and ethanol precipitation. 
2.11.4 RNA cloning and sequencing 
Sequencing libraries were constructed using the small RNA cloning protocol (Hafner et al. 2008) 
with barcoded pre-adenylated 3’adapters (2.13.3.1) and sequenced on Illumina GIIA and Hiseq2000 
platforms (Illumina, USA). 
 
2.12 Chromatin Immunoprecipitation (ChIP)  
2.12.1 Crosslinking and cell lysis 
After siRNA transfection, cells were grown for two more days. Three million cells were used for 
each ChIP assay. Cells were fixed with 1% formaldehyde (Roth, Germany) for 10 min at room 
temperature and reaction was stopped by adding glycine at a final concentration of 125 mM for 5 
min at room temperature. Cells were washed twice with ice-cold PBS + complete EDTA-free 
protease inhibitor cocktail (Roche, Switzerland) and harvested. Cells were resuspended in 1 ml cell 
membrane lysis buffer 1 (0.05 M Hepes-KOH pH 7.5, 0.14 M NaCl, 1 mM EDTA, 10% glycerol, 
0.5% NP-40, 0.25% Triton X-100, complete EDTA-free protease inhibitor cocktail (Roche, 
Switzerland)) and incubated for 15 min at 4°C with rotation. Nuclei were pelleted by centrifugation 
for 5 min at 4°C and 1000xg. Nuclei pellets were resuspended in 1 ml lysis buffer 2 (0.2 M NaCl, 1 
mM EDTA, 0.5 mM EGTA, 10 mM Tris pH 8, complete EDTA-free protease inhibitor cocktail 
(Roche)), incubated for 15 min at 4°C with rotation and pelleted by centrifugation again for 5 min 
at 4°C and 1000xg.  
2.12.2 Chromatin shearing 
Pellets containing nuclei were resuspended in 300 μl S1 sonication buffer (High Cell ChIP kit, 
Diagenode, USA) and sonicated for 12 cycles with 30 s on and 30 s off by using a Bioruptor (UCD-
300, Diagenode). The samples were centrifuged at 18,000xg for 5 min at 4°C to remove debris and 
detergents.  
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The sheared chromatin was diluted tenfold in ChIP dilution buffer (0.01% SDS, 1.1% Triton-X100, 
1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.1, 167 mM NaCl, complete EDTA-free protease inhibitor 
cocktail (Roche, Switzerland)).  
 
2.12.3 Immunoprecipitation 
To decrease unspecific binding of chromatin to magnetic beads, chromatin was precleared by 
adding 25 μl of protein G magnetic beads (Invitrogen, UK) to each IP reaction and incubated at 4°C 
for 1 h with agitation. The supernatants were separated from magnetic beads and 10% of the 
precleared chromatin was kept as an input control for further analysis. 5 μg of antibody was added 
for immunoprecipitation at 4°C over night with rotation. The antibodies used were anti-RNA 
polymerase II CTD YSPTSPS antibody (ab5408, Abcam), anti-RNA polymerase II CTD YSPTSPS 
(phospho S2) antibody (ab5095, Abcam), anti-RNA polymerase II CTD YSPTSPS (phospho S5) 
antibody (ab5131, Abcam), rabbit IgG isotype control (kch-504-250, Diagenode) and mouse IgG 
isotype control (M5284, Sigma-Aldrich). 
The next morning, after adding 25 μl of protein G magnetic beads (Invitrogen, UK), the reactions 
were incubated at 4°C for another 1 h with rotation. 
 
2.12.4 Washing and elution 
The beads were sequentially washed with the following washing buffers, once with low salt wash 
buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 150 mM NaCl), once 
with high salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 
500 mM NaCl), once with LiCl wash buffer (0.25 M LiCl, 1% IGEPAL-CA630, 1% sodium 
deoxycholic acid , 1mM EDTA, 10 mM Tris, pH 8.1) and twice with TE buffer (10 mM Tris-HCl, 1 
mM EDTA, pH 8.0.) at 4°C.  
100 μl of elution buffer (1% SDS, 0.1 M NaHCO3) was added to each IP reaction with incubation at 
RT for 15 min. Then a second round of elution with another 100 μl of elution buffer was performed. 
In the end, the two supernatants were combined as the final eluate. Elution buffer was also added to 
input control to get a final volume of 200 µl.  
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2.12.5 Reverse crosslinking and DNA purification 
8 μl of 5 M NaCl was added to each eluate with incubation at 65°C overnight for reverse 
crosslinking. The next morning, to digest RNA, 1 μl of 10 mg/ml RNase A (Roth, Germany) per 
reaction was added and incubated at 37°C for 30 min. Then, to digest proteins, 4 μl 0.5 M EDTA, 8 
μl 1 M Tris-HCl and  1μl of 20 mg/ml Proteinase K (Roche, Switzerland) were added into each 
reaction and incubated at 55°C for 1 h. DNA was extracted using Phenol/Chloroform extraction by 
adding 400 μl of Phenol/Chloroform/Isoamyl alcohol (v/v/v=25:24:1, Roth). Then, the aqueous 
phase was supplemented with 400 μl of Chloroform/Isoamyl alcohol (v/v=24:1, Roth) and 
centrifuged at 18,000xg for 5 min at room temperature. DNA was precipitated with 1 ml of ice-cold 
100% ethanol, 40 μl of 3 M sodium acetate and 1μl of Glycoblue (Ambion, USA) at -80°C for 30 
min. DNA pellets were washed with 70% ethanol, air-dried and resuspended in water. 
 
2.12.6 ChIP-qPCR and data analysis 
ChIP-qPCR primers designed to amplify 50 to 150 bp DNA fragments from selected genomic 
regions were first evaluated by amplification efficiency (AE) evaluation with a ten-fold dilution of 
input DNA as qPCR template. Only primers having an AE value between 0.90-1.10 were used for 
subsequent qPCR experiments. Input DNA, DNA from IgG control and sample DNA were diluted 
three fold in water. The same volumes of DNA from above were used as qPCR templates using 
Power SYBR Green PCR master mix (Applied Biosystem) on the StepOne Real-Time PCR System 
(Applied Biosystem, USA) for 30 cycles of 15 s at 94°C, 15 s at 60°C, and 20 s at 72°C. 
By visualization of amplification curves in StepOnePlus software (Applied Biosystems, USA), 
baseline adjustment was made if the reaction emerged before the default baseline (cycles 3 to 15). 
The ΔCt value (normalized to the input samples) was calculated for each sample: ΔCt [Ct (sample) - 
Ct (input)]. Then, the fold enrichment between experimental samples and input was computed by 
using formula 2(-ΔCt). 
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2.13 Oligonucleotides 
2.13.1 Primers 
All primers were ordered from MWG Eurofins (Germany).  
The following forward (_F) and reverse (_R) primers were used for PCR and cDNA cloning into 
pENTR4 (Invitrogen, UK), restriction sites are underlined: 
FUS_F  5’-ACGCGTCGACATGGCCTCAAACGATTATACCCAAC-3’,  
FUS_R  5’-ATAAGAATGCGGCCGCTCAATACGGCCTCTCCCTGCGATC-3’ 
FUS R495X_R 5'-ATAAGAATGCGGCCGCTTCAGAAGCCTCCACGGTCC-3' 
EWSR1_F  5’-ACGCGTCGACATGGCGTCCACGGATTACAGTA-3’,  
EWSR1_R  5’-ATAAGAATGCGGCCGCTTAGTAGGGCCGATCTCTGCGC-3’ 
TAF15_F   5’-ACGCGTCGACATGTCGGATTCTGGAAGTTACGG-3’,  
TAF15_R  5’-ATAAGAATGCGGCCGCTTAGTATGGTTGCGCTGAT-3’ 
TARDBP_F  5’-ACGCGTCGACATGTCTGAATATATTCGGGTAACCGAAGATG 
TARDBP_R  5’-TAAGAATGCGGCCGCCTACATTCCCCAGCCAGAAGACTTAG 
 
Knockdown efficiency of proteins was analyzed by qRT-PCR using primers: 
FUS qPCR_F    5’-GCCCTGGCAAGATGGATT-3’ 
FUS qPCR_R    5’-ACAAAAAGCTGTTCCAGAACCT-3’ 
EWSR1 qPCR_F   5’-AGCTACGGGCAGCAGAGTT-3’ 
EWSR1 qPCR_R    5’-CATGCTCCGGTTCTCTCC-3’ 
TAF15 qPCR_F   5’-GTCAAAACCAGCAGTCCTATCA-3’ 
TAF15 qPCR_R    5’-CTACTCACATCACGACGGTCA-3’ 
NME1-NME2 qPCR _F  5’-CCAATCCAGCAGATTCAAAG-3’  
NME1-NME2 qPCR _R  5’-CATAGGCTGATTTCTTTTTCAGC-3’ 
PTP4A1 qPCR _F   5’-GGCCACAATCTTCAATGAGTAA-3’ 
PTP4A1 qPCR _R   5’-TGCTGTGCCTGGCAGTAA-3’ 
NUCKS1 qPCR _F   5’-ATGGTTAAGAAGTCCAAACCTG-3’,  
NUCKS1 qPCR _R   5’-TTTGATGCCTTTGAAGCTGTG-3’  
GAPDH qPCR _F   5’-AGCCACATCGCTCAGACAC-3’ 
GAPDH qPCR _R    5’-GCCCAATACGACCAAATCC-3’ 
STK38 qPCR_F   5’-AGACATCAAACCAGACAACCTTC-3’ 
STK38 qPCR_R   5’-TCCTGTGCAAAGACCAAAGTC-3’ 
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SRSF3 qPCR_F   5’-GCCCTCGAGATGATTATCGTA-3’ 
SRSF3 qPCR_R   5’-CAGCGATCTCTCTCTTCTCCTATC-3’ 
SRSF3 qPCR_dn_F   5’-AAATGACTTGAGGGCGACAT-3’ 
SRSF3 qPCR_dn_R   5’-ATTGAACTGCACCCTGTGG-3’ 
CDKN1A qPCR_F   5’-TCACTGTCTTGTACCCTTGTGC-3’ 
CDKN1A qPCR_R   5’-GGCGTTTGGAGTGGTAGAAA-3’ 
For analysis of alternative splicing the following primers were used: 
ENAH_F    5’-AGCAAGTCACCTGTTATCTCCAG-3’ 
ENAH_R    5’-GTCCTTCCGTCTGGACTCC-3’ 
THAP6_F    5’-GAGATGTGTTGTGTTCGAGGC-3’ 
THAP6_R    5’-CCTTTGTATCCTCTAGCTCGC-3’ 
CSNK1D_F    5’-CGTCAACATCTCCTCGTCC-3’ 
CSNK1D_R    5’-GCACGACAGACTGAAGACC-3’ 
PDE8A_F    5’-GGCTTGTAACTCAGTATTCACTGC-3’ 
PDE8A_R    5’-TCCAATGACAGGTATTATCTTCACA-3’ 
 
The following primers were used for ChIP-qPCR: 
SRSF3 TSS_F   5’-AGGCGGTGGTCCGCCATTTC-3’ 
SRSF3 TSS_R   5’-CCGCTTTCCTCCGGCCCAAC-3’ 
GAPDH TSS_F   5’-TACTAGCGGTTTTACGGGCG-3’ 
GAPDH TSS_R   5’-TCGAACAGGAGGAGCAGAGAGCGA-3’ 
SRSF3 dn1_F    5’-CACAGAGGGATGACCGTGT-3’ 
SRSF3 dn1_R    5’-TCTGTCCCTGCTTGCAGAC-3’ 
SRSF3 dn2_F    5’-ACCGTGTGAGGAGGCAGTAG-3’ 
SRSF3 dn2_R    5’-ACCGTGTGAGGAGGCAGTAG-3’ 
SRSF3 dn4_F    5’-GGCTCCGCTTTCTCAGAGTT-3’ 
SRSF3 dn4_R    5’-AGCCTGTGGTGATGGTGATG-3’ 
SRSF3 3'UTR_F   5’-GAAACACAGGCCATCAGGGA-3’ 
SRSF3 3'UTR_R   5’-ACCAACTAGGCAACCTCTGC-3’ 
GAPDH 3’UTR_F   5’-CCCCCACCACACTGAATCTC-3’ 
GAPDH 3’UTR_R   5’-TGGTTGAGCACAGGGTACTT-3’ 
Untr control1_F   5’-AAGTTATCATCCTGGTGAGTTGC-3’ 
Untr control1_R   5’-AGGTAATTAATCTGCTACTCTGGGA-3’ 
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The following primers were used for PAR-CLIP: 
3’ PCR primer   5’-CAAGCAGAAGACGGCATACGA-3‘ 
5’ PCR primer   5‘-AATGATACGGCGACCACCGACAGGTTCAGAGTTCTAC 
    AGTCCGA-3‘ 
2.13.2 siRNAs 
The following siRNA duplexes (sense/antisense) were used for knockdown experiments. TAF15 
siRNAs were designed as described by (Jobert et al. 2009). All siRNA duplexes were purchased 
from Sigma-Aldrich (Germany): 
FUS duplex 1, GAUCAAUCCUCCAUGAGUAdTdT, UACUCAUGGAGGAUUGAUCdTdT,  
FUS duplex 2, CAGAGUUACAGUGGUUAUAdTdT, UAUAACCACUGUAACUCUGdTdT,  
EWSR1 duplex 1, GACUCUGACAACAGUGCAAdTdT, UUGCACUGUUGUCAGAGUCdTdT,  
EWSR1 duplex 2, GCCAAGCUCCAAGUCAAUAdTdT, UAUUGACUUGGAGCUUGGCdTdT,  
TAF15 duplex 1, UGAUCAGCGCAACCGACCAdTdT, UGGUCGGUUGCGCUGAUCAdTdT,  
TAF15 duplex 2, GGACAGAACUACAGCGGUUdTdT, AACCGCUGUAGUUCUGUCCdTdT 
 
2.13.3 Adapters 
2.13.3.1 PAR-CLIP adapters 
5’adapter  
oR5-NN  5’-GUUCAGAGUUCUACAGUCCGACGAUCNN-3‘ 
3’adapters 
NN-NBC1  5’-NNAAAATCGTATGCCGTCTTCTGCTTG-3’  
NN-NBC2  5’-NNCCCATCGTATGCCGTCTTCTGCTTG-3’  
NN-NBC3  5’-NNGGGATCGTATGCCGTCTTCTGCTTG-3’  
NN-NBC4  5’-NNTTTATCGTATGCCGTCTTCTGCTTG-3’  
NN-NBC5  5’-NNCACGTCGTATGCCGTCTTCTGCTTG-3’ 
NN-NBC6  5’-NNCCATTCGTATGCCGTCTTCTGCTTG-3’ 
NN-NBC7  5’-NNCGTATCGTATGCCGTCTTCTGCTTG-3’ 
NN-NBC8  5’-NNCTGCTCGTATGCCGTCTTCTGCTTG-3’ 
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2.13.3.2 Small RNA cloning adapters 
5’adapter  
oR5-NN  5’-GUUCAGAGUUCUACAGUCCGACGAUCNN-3‘ 
3’adapters 
NBC1 5’-TCTaaaaGTATGCCGTCTTCTGCTTGT-3’ 
NBC2 5’-TCTcccaGTATGCCGTCTTCTGCTTGT-3’ 
NBC3 5’-TCTgggaGTATGCCGTCTTCTGCTTGT-3’ 
NBC4 5’-TCTtttaGTATGCCGTCTTCTGCTTGT-3’ 
NBC5 5’-TCTcacgGTATGCCGTCTTCTGCTTGT-3’ 
NBC6 5’-TCTccatGTATGCCGTCTTCTGCTTGT-3’ 
NBC7 5’-TCTcgtaGTATGCCGTCTTCTGCTTGT-3’ 
NBC8 5’-TCTctgcGTATGCCGTCTTCTGCTTGT-3’ 
 
2.14 Computational methods 
Data analysis as described below was conducted by Marvin Jens, PhD student in the group of 
Nikolaus Rajewsky at the Berlin Institute for Medical Systems Biology at the Max-Delbrück Center 
for Molecular Medicine ( Robert-Rössle Str. 10, D-13125 Berlin, Germany)  
2.14.1 PAR-CLIP computational pipeline 
All sequencing data sets were run with a pipeline that performed all steps of the analysis from raw 
reads to cluster sets and target genes, in a largely automated and unbiased way. The emphasis was 
on stringent filtering and controlling the false-positive rate in the identification of binding sites. 
Reads were collapsed into distinct sequences (counting each sequence only once) and aligned to the 
reference genome assembly hg18 allowing for up to one mismatch, insertion or deletion. Only 
uniquely mapping reads were retained. Clusters of aligned CLIP-seq reads were identified that 
continuously covered regions of genomic sequence. 
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 A number of additional quality scores to each cluster were also assigned, based on read coverage, 
the relative frequency of characteristic conversions and uniqueness of alignments: 
• number of (unique, distinct) read alignments 
• number of characteristic mismatches (T to C, G to A,...) 
• length of the cluster 
• entropy score over read start/end positions 
• entropy score over read sequence variability 
• maximum uniqueness of all alignments that support a cluster 
 
Uniqueness refers to the margin between the reported, best alignment of a read and the second best 
alignment considered by the read mapper.  
As the aggregate amount of sense and antisense sequence is identical (ambiguous cases are put 
aside), one can regard the reverse complement of all transcripts, as an approximately fair decoy 
database. In the absence of any real biological signal in the PAR-CLIP data an equal number of 
clusters to hit sense and antisense may be expected. Such a decoy database, therefore introduces a 
simple estimator of the false discovery rate (FDR) in the set of all PAR-CLIP read clusters: 
 
FDR = (#antisense + 1)/(#sense + #antisense + 2)  
 
where #sense and #antisense refer to the number of sense and antisense clusters, respectively. 
With the FDR estimator at hand, it is possible to assess the effect of filtering the cluster set by 
setting thresholds on their quality scores. If the antisense clusters indeed represent mapping 
artifacts, the corresponding quality score distribution should differ from the sense clusters, which 
supposedly contain the true-positives. This would allow finding cutoffs that deplete false-positives 
more strongly than true-positives and improve the FDR. It is important to bear in mind, that 
mapping artifacts may also align sense to known transcripts. Utilizing the antisense clusters to 
select cutoffs will arguably serve to also deplete the false-positives among the sense aligning 
clusters. On the other hand, the filtering should discard as little real data as possible. To find the best 
compromise, the pipeline code iterates over each of the aforementioned cluster quality scores and 
estimates the FDR at each quality score that actually appears in the data, effectively probing the 
whole range of possible cutoffs. 
27 
 
 Materials and methods  
 If a score cutoff serves to reduce the FDR below a desired limit (FDR < 5%) it is recorded, together 
with the number of sense clusters that surpass the cutoff and would be retained. Out of all 
score/cutoff combinations that satisfy the FDR limit, the one preserving the largest number of sense 
aligning clusters is chosen. After the cutoff is applied, remaining decoy clusters are discarded and a 
cluster set is reported that can be expected to satisfy the FDR constraint. 
In order to screen for evidence of potential interactions between FET proteins and splice sites, we 
performed a reciprocal analysis. Taking a particular set of processing sites (e.g.3' splice sites) we 
scanned for the presence or absence of PAR-CLIP coverage in the neighbourhood of all sites. The 
windows of zeros and ones (indicating absence or presence of at least one aligned read) were 
accumulated and averaged to yield the average probability for finding at least one PARCLIP read at 
a given distance. 
2.14.2 Sequence motif analysis 
6-mer occurrences were counted in 41nt windows around preferred crosslink sites identified in the 
4SU and 6SG PAR-CLIP experiments. 6-mers with less than 10 occurrences were discarded from 
the analysis. The frequency of the remaining 6-mers was compared to all reference sequences 
(RefSeq) 3'UTR sequences or introns as a representative background set (Lebedeva et al. 2011). 
2.14.3 RNA secondary structure analysis 
To test whether FET binding sites showed a preferred secondary structure the library routines from 
the Vienna RNA package 1.8.2 (Hofacker 2004) were used to compute base pairing probabilities 
within 201nt sequences centered on the preferred crosslink positions of binding sites. The resulting 
profiles were accumulated and averaged over all sites. Randomly chosen positions served as a 
control. 
2.14.4 Gene ontology term analysis 
Target genes were subjected to GO term analysis using the web-based DAVID functional annotation 
tool (Huang et al., 2009 1 and 2). 
2.14.5 RNA-Seq quantification 
Polyadenylated RNA from mock-transfected cells and siRNA treated cells were sequenced on 
Illumina Genome Analyzer GAII or Illumina HiSeq (Illumina, USA) using 2x76 bp paired-end kits.  
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All obtained paired-end reads were mapped to the hg18 genome sequence (Pruitt et al. 2005) with 
tophat (Trapnell et al. 2009). The quantification utility CUFFDIFF from the CUFFLINKS RNA-
Seq toolchain (Trapnell et al. 2010) was used to estimate gene and isoform FPKM-levels and 
confidence intervals using the aligned reads and the RefSeq gene models. Log2 fold changes were 
computed from the inferred gene-level FPKM values from siRNA and mock-transfected samples. 
We computed log fold changes only for genes that had >= 5 FPKM in either of the compared 
samples and added a pseudo-count of 10 FPKM to reduce noise from low expression and avoid 
divisions by zero. 
 
2.14.6 3’UTR extension analysis 
A small RNA library from RNase-I digested poly(A)+ mRNA (provided by M. Munschauer), was 
utilized to unbiasedly annotate transcribed regions in the genome of HEK293T-Rex cells with 
strand information. Regions that contained more than 10 aligned reads within a kilobase were 
merged into “islands” and annotated against the RefSeq annotation [RefSeq consortium, BLAT, 
UCSC genome browser]. In this manner, 3' extensions of known transcription units were identified 
by strand and proximity to or overlap with known sites of cleavage and polyadenylation. Such 
3'UTR extension regions were then scored for the number or polyA mRNA-Seq reads aligning to 
them in unperturbed (mock) and FET-protein loss of function conditions (RNAi knockdown) to 
identify regions of putative FET-protein dependent transcription. 
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3. Results 
3.1 Generation of cell lines for stable, inducible expression of epitope-tagged 
FET proteins  
To identify RNA and DNA elements interacting with FUS, EWSR1 and TAF15, HEK293 cell lines 
stably inducible expressing N-terminal FLAG/HA-tagged versions of the proteins were generated. 
The FLAG/HA-tag of the proteins was then used to efficiently immunoprecipitate the recombinant 
proteins for further experiments (PAR-CLIP and ChIP). Likewise, a cell line for the FUS variant 
R495X found in patients with ALS was generated for comparison. This mutation lacks a putative 
nuclear localization signal at the C-terminus of FUS. 
Cell lines were generated by cloning and recombination the respective coding sequence of FUS, 
EWSR1, TAF15 and the FUS mutant R495X using the FLP-In T-Rex System (Invitrogen). 
Expression of the recombinant proteins is controlled by a Tet operator allowing for specific 
induction of protein expression after addition of doxycycline. The epitope-tagged proteins were 
induced to expression levels lower than the respective endogenous proteins as observed by Western 
blot analysis (Fig.5) using protein-specific antibodies to detect endogenous (lower band) as well as 
FLAG/HA-tagged FET proteins (upper band). 
This indicates that the expression level of recombinant FET proteins is comparable with the level of 
endogenous FET proteins. 
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Fig. 5: Generated cell lines for stable, inducible expression of FLAG/HA-tagged FET proteins. 
Western blot analysis of cell lysates before and after induction of recombinant protein expression with doxycycline. 
Samples were analyzed by Western blotting with antibodies against FUS, EWSR1, TAF15 (upper panels) and HA-
epitope (middle panels). Due to the C-terminal mutation FUS R495X cannot be detected by anti-FUS. ß-Tubulin was 
detected as a loading control (lower panels). 
3.2 Identification of FET protein RNA targets by PAR-CLIP  
To identify RNA elements interacting with FUS, FUS R495X, EWSR1 and TAF15 the recently 
developed PAR-CLIP method was applied followed by next-generation sequencing (Hafner et al. 
2010) (Tab.2). During the PAR-CLIP experiments cellular RNA is labeled with either 4-thiouridine 
(4SU) or 6-thioguanosine (6SG) and crosslinked to bound proteins (Fig.6A). Efficient crosslinking 
leads to specific nucleotide transition events during the reverse transcription step in library 
preparation from each experiment: crosslinked 4SU and 6SG residues are converted into C and A, 
respectively (Fig.6B), providing a diagnostic mark at nucleotide resolution of the RBP binding site 
on target RNAs (Hafner et al. 2010).  
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Tab. 2: Overview of PAR-CLIP experiments and samples. 
 4-SU PAR-CLIP libraries 6-SG PAR-CLIP libraries 
FUS 4x 1x 
FUS R495X 1x 1x 
EWSR1 2x  
TAF15 2x 1x 
TARDBP 2x 1x 
TARDBP M337V 1x  
 
 
All PAR-CLIP sequencing data were analyzed with a recently described computational pipeline 
(Lebedeva et al. 2011) to determine the binding sites at an estimated 5% FDR from filtered clusters 
of aligned reads. To define a PAR-CLIP consensus, clusters that were not supported by reads from 
at least 3 out of 5 FUS libraries, 2 out of 2 EWSR1 libraries, 2 out of 3 TAF15 libraries, 2 out of 3 
TARDBP libraries and 2 out of 2 FUSR495X libraries (biological replicates) were discarded. The 
number of T to C or G to A mismatches (4SU, 6SG characteristic conversions) served as a crosslink 
score (Hafner et al. 2010). As PAR-CLIP cDNA reads are typically short and their sequence is 
mutated by 4SU-induced crosslinking, they cannot be expected to always align correctly to the 
reference sequence. A certain fraction will produce false alignments, leading to false-positive 
binding sites. However, as the bound RNA fragments derive from biological, naturally occurring 
RNA and the sequencing strategy preserves strand information, the true-positives can be expected 
to align predominantly sense to known transcripts. Clusters aligning antisense to known transcripts, 
on the other hand, can be regarded as false-positives. In a few cases they may be true-positives, 
derived from un-annotated antisense transcripts, but these will be rare and typically much less 
abundant. Stranded sequencing data was used to comprehensively annotate regions of transcription, 
adding significant amounts of apparently true antisense transcripts to the RefSeq catalog. 
Consequently, treating remaining antisense aligning clusters as false-positives, is a conservative 
assumption because it can only over estimate the number of false-positives produced by alignment 
artifacts. 
The numbers of obtained sequence clusters ranged from 55.000 to 232.000 for the four proteins 
targeting 6.591 to 11.470 genes which encode up to 78% of all proteins expressed in HEK293 cells. 
Figure 6D shows an example of aligned reads and transition events for the FUS target CDK1. A 
mean length of 25 nt for filtered FUS, EWSR1, and TAF15 sequence clusters demonstrates the 
high-resolution of PAR-CLIP data (Fig.6C).  
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Fig. 6:  PAR-CLIP of FET proteins. 
(A) Efficient UV 365 nm crosslinking of 4SU-containing RNA to FET proteins. Phosphoimages of SDS-PAGE gels 
resolving radiolabeled RNA- FET protein-immunoprecipitates are shown in the upper panel. Expression of FLAG/HA-
tagged FET proteins was induced by doxycycline and cells were cultured in the absence (-) or presence (+) of 4SU. 
Equal amounts of immunoprecipitated protein was confirmed by Western blot analysis using an anti-HA antibody 
(lower panel). (B) Crosslinking of 4SU or 6SG-labeled RNA resulted in specific mismatches during RT-PCR which are 
characterized by T to C and G to A conversions, respectively. The frequency of nucleotide mismatches in PAR-CLIP 
reads is shown for 4SU (red) and 6SG (blue). (C) Example of length distribution of PAR-CLIP clusters for a 4SU (red) 
and 6SG library (blue). (D) Representative example of PAR-CLIP data. The read coverage (black) and nucleotide 
conversions (red) are given together with FUS binding sites (blue boxes) and repetitive elements (black boxes) for the 
CDK1 transcript. Sequences which cannot be mapped uniquely due to repetitive elements are discarded. Insert: 
Example of a FUS cluster with T to C conversions highlighted in red and G to A conversions highlighted in blue.  
 
 
RBP binding sites are defined in the PAR-CLIP computational pipeline as clusters of overlapping or 
directly adjacent sequencing reads which contain characteristic nucleotide conversions. Uniquely 
aligning reads were grouped into read clusters. Clusters mapping antisense to known transcripts 
were used to estimate the FDR. Clusters overlapping repetitive elements were discarded. 
The majority of clusters identified for the three FET proteins mapped to transcripts derived from 
protein-coding genes. About 90% of the FUS and EWSR1 mRNA-mapping clusters aligned to 
intronic sequences, consistent with the nuclear localization of these two proteins (Andersson et al. 
2008), whereas TAF15 sequence clusters were nearly equally distributed in introns and 3’UTRs 
(Fig.7A). As expected, for the FUS variant R495X, which localizes predominantly to the cytoplasm 
due to the loss of the C-terminal nuclear localization signal (Fig.7B), a change in the distribution of 
binding sites was observed compared to the wild-type protein resulting from a reduction in intronic 
binding sites likely due to its loss of the NLS.  
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Fig. 7: Comparison of FET and FUS R495X binding sites. 
(A) Distribution of FET and FUS R495X binding sites along transcripts. For EWSR1 and FUS most of the binding sites 
are located in introns. For TAF15 a larger proportion of binding sites are also located in 3’UTRs. Due to the altered 
cytoplasmic localization of FUS R495X, the number of intronic binding sites is reduced compared to FUS. (B) 
Differences in localization of wildtype and FUS R495X mutant. FLAG/HA-tagged FUS and FUS R495X expressing 
HEK293 cells were stained with an anti-HA antibody (green), the nuclear counter stain TO-PRO-3 (blue) and analyzed 
by microscopy. Images were provided by Dr. Dorothee Dormann, DZNE, Ludwig-Maximilians-Universität München. 
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3.3 Identification of TARDBP RNA targets and binding sites 
In 2006, TARDBP/TDP-43 was identified as a major component of ubiquitinated inclusions in the 
central nervous system of patients with ALS and FTLD (Neumann et al. 2006). Shortly after, 
mutations in TARDBP were discovered as causative of ALS and FTLD cases (Neumann et al. 2006; 
Kabashi et al. 2008; Sreedharan et al. 2008). Mutations in a second RBP, FUS, were identified in 
familial ALS patients as well as in rare FTLD cases (Neumann et al. 2009; Vance et al. 2009). 
TARDBP is structurally unrelated to FET proteins, but likewise, ubiquitinated cytoplasmic 
inclusions containing TARDBP are observed in disease-affected tissues (Neumann et al. 2006). 
These genetic findings and the common pathology indicate that both FUS and TARDBP proteins 
abnormally aggregate in ALS and FTLD, and suggest similar RNA targets and molecular 
mechanisms aberrantly regulated at the post-transcriptional level as potential pathogenic clues. 
For comparison, cell lines of TARDBP and the ALS related TARDBP mutant M337V were 
generated and PAR-CLIP was performed (Fig.8A). The genomic annotation of the TARDBP 
sequence clusters is consistent with previous reports of TARDBP binding patterns in embryonic 
stem cells, SH-SY5Y neuroblastoma cells and human brain (Tollervey et al. 2011; Xiao et al. 2011). 
In comparison with PAR-CLIP data of the FET proteins, close to 70% of TARDBP sequence 
clusters were found in introns of protein-coding transcripts (Fig.8B), in agreement with HITS-CLIP 
and iCLIP data (Polymenidou et al. 2011; Tollervey et al. 2011). Even more intronic binding sites 
were found for the TARDBP mutant M337V, which in contrast to the FUS R495X mutant shows no 
altered localization in the cell compared to the wild type protein (Fig.8C). 
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Fig. 8: Comparison of TARDBP and TARDBP M337V binding sites. 
(A) Phosphoimage of SDS-gel resolving radiolabeled RNA-TARDBP immunoprecipitates are shown in the upper 
panel. Expression of FLAG/HA-tagged TARDBP was induced by doxycycline and cells were cultured in the absence (-
) or presence (+) of 4SU. Equal immunoprecipitation was confirmed by Western blot analysis using anti-HA (lower 
panel). (B) Distribution of TARDBP and TARDBP mutant M337V binding sites along transcripts.  (C) Nuclear 
localization of wildtype and TARDBP M337V mutant. FLAG/HA-tagged TARDBP and TARDBP M337V expressing 
HEK293 cells were stained with an anti-HA antibody (green), a nuclear counter stain (blue) and analyzed by 
microscopy.  Images were provided by Dr. Dorothee Dormann, DZNE, Ludwig-Maximilians-Universität München. 
3.4 Overlap of FET and TARDBP mRNA targets 
In order to obtain insight whether FUS, EWSR1 and TAF15 regulate different sets of transcripts, the 
top 1000 target mRNAs ranked by T-to-C frequency were examined (Fig.9A). This comparison 
revealed that FUS and EWSR1 overlap in 643 targets and all three family members share 426 
mRNA targets.  Gene ontology (GO) term analysis (Huang da et al. 2009b; Huang da et al. 2009a) 
of mRNAs bound by all three FET proteins revealed an enrichment of the GO terms “ubiquitin 
mediated proteolysis”, “cell cycle” and “RNA degradation”. Furthermore, mRNA targets of the 
ALS related protein TARDBP also overlap substantially with FUS and FUS R495X targets. 
B A C 
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Intersection of the top 2000 FUS, FUS R495X and TARDBP targets revealed 908 overlapping 
targets (Fig.9B). These target genes were subjected to GO term enrichment analysis. The most 
enriched category suggests also an involvement of FET proteins and TARDBP in the regulation of 
the ubiquitin-mediated proteolysis pathway. 
 
 
Fig. 9: Comparison of FET and TARDBP mRNA targets. 
(A)  Overlap of top 1000 mRNA targets of FUS, EWSR1 and TAF15, together with enriched GO terms among FET 
overlapping targets. (B) Overlap of top 2000 mRNA targets of FUS, FUS R495X and TARDBP with GO term analysis 
of overlapping targets. GO term analysis was conducted with the DAVID online tool (Huang da et al. 2009b). 
3.5 FUS and TAF15 recognize different motifs than EWSR1 
Next, 4SU and 6SG PAR-CLIP data were used to identify RNA sequences that were preferentially 
recognized by FET proteins. Since only uridine (U) containing binding sites can be captured by 
using 4SU in PAR-CLIP experiments, the 6SG PAR-CLIP data were used to capture also sequences 
devoid of Us. Hence, the 6mer occurrence in 41 nt window centered on the anchor was counted. An 
anchor corresponds to the position in a cluster with the highest frequency of nucleotide transitions 
and therefore represents the preferred binding site (crosslink centered region, CCR).  
A B 
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Among the most abundant words preferentially bound by the FET proteins, UAC containing 
sequences are clearly enriched for FUS and TAF15 (Fig.10A). Interestingly, for EWSR1 GC-rich, 
but no UAC-rich sequences, were enriched among the top motifs.  
We analyzed our TARDBP PAR-CLIP data the same way and counted the 6mer occurrence around 
the anchor. The most significantly enriched hexamer was UGUGUG (Fig.10A) as recently 
discovered by iCLIP (Tollervey et al. 2011). 
Furthermore, the PAR-CLIP data were used to investigate whether FET binding sites have any 
specific predicted secondary structure. RNA secondary structure can be a feature contributing to the 
specificity of RBPs (Buratti and Baralle 2004). The FET proteins have been proposed to bind to 
AU-rich stem-loop structures (Hoell et al. 2011). Therefore, the binding sites of FET proteins in 
introns were computationally folded and the resulting base pairing probabilities were averaged. We 
found a substantially reduced base-pairing probability in the direct vicinity of FUS, EWSR1 and 
TAF15 anchors with no indication of a hairpin structure (Fig.10B).  
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Fig. 10: FET binding motif preferences. 
(A) Correlation between 6mer frequencies in FET PAR-CLIP experiments versus matched control regions. Pearson and 
Spearman rank correlation coefficients are indicated. (B) FET proteins bind preferentially single stranded regions. 41 nt 
sequence contexts around FET binding sites were computationally folded and the average base pairing probability was 
determined. 
 
 
 
 
3.6 Knockdown of FET proteins reduces target mRNA abundance 
To test whether the large number of FET interactions uncovered by PAR-CLIP were functional and 
to study the influence of the FET family on gene expression, FUS, EWSR1 and TAF15 were 
depleted in HEK293 cells by siRNA mediated knockdown using two different siRNAs for each 
protein. Since FUS, EWSR1 and TAF15 may be redundant, all three proteins were depleted at the 
same time (triple knockdown) as well.  
Knockdown efficiency of different siRNAs was validated by qRT-PCR and Western blot (Fig.11). 
FUS, EWSR1 and TAF15 are abundant proteins and therefore a high efficiency of the knockdown 
was required to achieve a reproducible and effective response. The knockdown efficiency quantified 
by qRT-PCR ranged between 3 to 5 fold for the three FET proteins.  
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Fig. 11: Validation of FET knockdown. 
(A) Quantitative RT-PCR on total RNA from cells after FET knockdown using GAPDH for normalization. Error bars 
represent the standard deviation for three technical replicates. (B) Cell lysates of FUS, EWSR1, TAF15 siRNA treated 
and untreated cells (mock) were immunoblotted and probed with anti-FUS, anti-EWSR1, anti-TAF15 (upper panels) 
and anti-β-Tubulin (lower panels).  
 
 
To examine the effect of FET protein binding on the transcriptome, changes on transcript levels 
were monitored upon FET perturbation by next generation paired-end mRNA-Seq. Transcript 
expression levels were estimated from the sequencing data using the CUFFLINKS RNA-Seq 
toolchain (Trapnell et al. 2010). Hierarchical clustering showed that the changes in mRNA 
abundance induced by knockdown using two siRNAs for the same protein are more similar than to 
those targeting the other proteins (Fig.12).  
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Fig. 12: Hierarchical clustering of mRNA target changes upon FET protein depletion. 
Hierarchical clustering diagram of log 2 fold mRNA changes after FUS, EWSR1 and TAF15 knockdown using two 
different siRNAs for the same protein. 
 
To compare the effect of depletion of FUS, EWSR1 or TAF15 on various sets of transcripts, 
cumulative density fractions of changes in mRNA abundance were calculated (Fig.13A). For FUS, 
EWSR1 and TAF15 mRNA abundance of the identified mRNA targets by PAR-CLIP are 
significantly more downregulated than non-targets (black), confirming the overall functionality of 
PAR-CLIP targets. The top 1000 mRNA targets with most binding sites showed strongest 
downregulation.  
In addition, downregulation of selected mRNA targets upon FUS knockdown were validated by 
qRT-PCR (Fig.13B). Since most of the binding sites were observed in intronic sequences, these 
observations suggest that FET proteins facilitate the processing of their target transcripts.  
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Fig. 13: Effects on mRNA expression of target transcripts after FET protein knockdown. 
(A) Cumulative distribution functions of mRNA log 2 fold changes. Abundance of FET target mRNAs are 
downregulated upon knockdown of FUS, EWSR1 and TAF15 compared to non-targeted mRNAs. The p-values indicate 
the significance of difference between the changes of target versus nontarget transcripts, as given by Wilcoxon rank-
sum test. (B) Validation of downregulation of selected targets after FUS knockdown by quantitative RT-PCR. 
Expression of target mRNAs was normalized to GAPDH and is shown relative to mock transfection. Error bars 
represent the standard deviation for three technical replicates. 
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3.7 FUS and EWSR1 dependent changes in alternative splicing 
To assess the distribution of FET protein binding within introns especially around splice sites, the 
neighborhood of such sites was scanned for the presence or absence of PAR-CLIP reads. FUS, 
EWSR1, and TAF15 bind to proximal intronic sequences with a preference toward the 5’ and 3’ 
splice sites (Fig.14). For all three FET proteins a sharp peak could be seen around 20 nucleotides 
upstream of the 3’ splice site and for FUS and EWSR1 also a broader peak downstream of the 
5’splice site. Similarly, the intronic binding sites of TARDBP were found close to splice sites, as 
demonstrated previously (Tollervey et al. 2011).  In contrast, compared to the wild type FUS 
protein, the FUS mutant R495X shows reduced binding upstream of the 3’ splice site and 
downstream of the 5’ splice site. The stronger binding pattern of all three FET proteins upstream of 
the 3’ splice site is overlapping with the predicted polypyrimidine tract which is located 5 to 40 base 
pairs before the 3’ end of the intron (Reed 1989). This confirms the previous observation that the 
FET proteins might be involved in regulation of alternative splicing as previously published (Hallier 
et al. 1998; Paronetto et al. 2011; Ibrahim et al. 2013). 
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Fig. 14: Distribution of FET binding sites around splice sites. 
The vicinity of 5’ and 3’ splice sites of all RefSeq transcripts were scanned for the presence of at least one PAR-CLIP 
read of FUS, FUS R495X, EWSR1, TAF15 and TARDBP (PAR CLIP read density on a relative scale from 0 to 100%). 
FET and TARDBP PAR-CLIP reads are enriched near 3’ and 5’splice sites (arrows) in contrast to the FUS mutant 
R495X.  
 
The binding of FET proteins to proximal intronic sequences, the association with splicing factors 
(Meissner et al. 2003) and already published experimental evidence indicate an involvement of FUS 
and EWSR1 in alternative splicing. FUS was shown to regulate alternative splicing in mouse 
neurons pointing to a connection of RNA processing and the development of ALS (Kino et al. 
2011; Rogelj et al. 2012). EWSR1 depletion in HeLa cells leads to an altered splicing of genes 
involved in DNA repair and genotoxic stress responses (Paronetto et al. 2011). This prompted us to 
examine the mRNA sequencing data for genes with FUS, EWSR1, and TAF15-dependent splicing. 
Therefore, the RNA-Seq data after FET knockdown were screened for differences in expression of 
alternative spliced isoforms using the quantification utility CUFFDIFF from the CUFFLINKS 
RNA-Seq toolchain (Trapnell et al. 2010). For FUS the PSI (Percent Spliced In) ratio was 
quantified for 13 candidate exons with PCR amplification of both isoforms and Bioanalyzer 
analysis of the PCR products. PSI (percent spliced in) values were calculated as the molar ratio of 
the peak corresponding to the exon containing isoform and the sum of the peaks representing both 
isoforms. For FUS splicing changes for 7 out of 13 in two independent biological replicates could 
be validated (Fig.15). For EWSR1 the splicing change for 3 out of 7 in two independent biological 
replicates was validated (Fig.15).   
 
 
 
48 
 
 Results  
 
Fig. 15: Effects on alternative spliced exons after FUS and EWSR1 depletion. 
Genomic loci centered on alternative exons flanked by constitutive exons are shown in blue. FUS and EWSR1 binding 
sites (red) are shown together with coverage profiles of RNA-Seq for mock- and siRNA-transfected cells. Differential 
inclusion of alternative exons was validated by PCR with primers to the flanking exons. The PSI (Percent Spliced In) 
value was calculated from molar ratios of the PCR products quantified by Bioanalyzer. Error bars represent the standard 
deviation for three technical replicates. 
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3.8 Knockdown of FET protein alters mRNA expression of the SRSF3 locus 
Since FET proteins were implicated in transcriptional regulation by associating with RNA Pol II 
and the transcription factor TFIID (Bertolotti et al. 1996), a focused investigation of FET proteins in 
transcription based on the example of the SRSF3 region was performed. For FUS, EWSR1 and 
TAF15 binding sites were found along the SRSF3 gene and for FUS and EWSR1 also around 50 kb 
further downstream (Fig.16A). Furthermore transcription of this locus is supported by RNA-Seq 
coverage of mock and FUS siRNA-transfected cells. RT-PCR revealed that this transcript likely is a 
read-through product of the serine/arginine-rich factor 3 (SRSF3) gene. Furthermore, this 
observation is supported by protein occupancy profiling on mRNA (Baltz et al. 2012). For the 
SRSF3 locus, but also 50 kb downstream, high levels of T-C transitions were observed indicative for 
regions of increased protein binding. SRSF3 belongs to the serine/arginine (SR)-rich family which 
is part of the spliceosome. SR proteins have been shown to be critical for mRNA splicing as well as 
mRNA export (Huang and Steitz 2001). Furthermore, SRSF3 is critical for cell proliferation and 
tumor induction because knockdown of SRSF3 leads to cell cycle arrest and apoptosis in U2OS 
sarcoma cells (Jia et al. 2010). In addition, SRSF3 was identified as an important internal ribosome 
entry site (IRES) trans-acting factor for poliovirus IRES-mediated translation (Fitzgerald and 
Semler 2011). Upon poliovirus infection SRSF3 re-localizes from the nucleus to cytoplasm where it 
interacts with PCBP2 to recruit ribosomes. 
Quantitative RT-PCR of FET-depleted cells revealed no change in SRSF3 mRNA level but a 2.5-
fold increase of RNA derived from a locus 50 kb downstream of SRSF3 (Fig.16B). Furthermore a 
4-fold upregulation in expression of the SRSF3 flanking gene CDKN1A and mild upregulation of 
STK38 was seen. These data raised the possibility that FUS and EWSR1 might influence 
transcription of this genomic region. Another study by Schwartz et al., which was published 
meanwhile, showed that loss of FUS leads to an accumulation of RNA Pol II at the transcriptional 
start site (TSS) and premature polyadenylation of transcripts (Schwartz et al. 2012). In their study, 
FUS knockdown led to production of shorter isoforms for 47 manually checked mRNAs and longer 
isoforms for 15 mRNAs. In our study, FET protein knockdown for the SRSF3 locus led to 
production of a longer SRSF3 mRNA isoform. 
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Fig. 16: Specific binding of FUS and EWSR1 to a downstream region of SRFS3. 
(A) Distribution of binding sites of FET proteins and TARDBP around the SFRS3 locus. RNA-Seq coverage of FUS 
siRNA1 and mock transfected cells, as well as protein occupancy (orange) together with T-C conversions (black) and 
the PhyloP mammalian conservation score (green) are also shown. (B) Quantitative RT-PCR results are shown after 
depletion of all three FET proteins at the same time (Triple KD) for STK38, SRFS3, a region 50 kb downstream of 
SRFS3 (SRSF3 extension) and CDKN1A are shown together with the respective location of the qPCR amplicons. 
Expression levels were normalized to GAPDH. Error bars represent the standard deviation for three technical replicates. 
 
Next, we asked whether this is a direct effect of the FET proteins on transcription by interaction 
with RNA Pol II. A role for the FET proteins in transcription was already suggested by several 
studies. All three FET proteins were found to co-purify with the transcription factor TFIID and 
RNA Pol II (Bertolotti et al. 1996; Hoffmann and Roeder 1996; Bertolotti et al. 1998). Furthermore, 
FUS interacts with the TATA-binding protein which enhances RNA Pol II transcription (Tan and 
Manley 2010). Schwartz and coworkers revealed that FUS is able to bind the C-terminal domain 
(CTD) of RNA Pol II orchestrating CTD phosphorylation (Schwartz et al. 2012). Transcriptional 
elongation is influenced by the phosphorylation state of the CTD which serves as platform for 
factors regulating transcription. Phosphorylation activates RNA Pol II and triggers transcriptional 
initiation. Phosphorylation occurs mainly at Ser2 and Ser5 of the heptapeptide repeat. The 
phosphorylation status of the CTD changes at different positions along the transcription unit. 
Phosphorylation of Ser5 residues predominates near the beginning of genes, whereas polymerases 
near the ends of genes are extensively phosphorylated on Ser2 residues (Komarnitsky et al. 2000; 
Morris et al. 2005).  
B 
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Schwartz and colleagues suggested that FUS modulates the amount of Ser2 phosphorylation around 
the TSSs as loss of FUS leads to an accumulation of phosphorylated Ser2 at the TSSs (Schwartz et 
al. 2012). 
To test an influence of FET proteins on transcription of the SRSF3 locus, genome-wide localization 
of RNA Pol II on the chromatin of HEK293 cells using ChIP followed by qRT-PCR was examined. 
Three different RNA Pol II antibodies were used to immunoprecipitate different phosphorylated 
forms of RNA Pol II. The RNA Pol II antibody CTD4H8 (ab5408, Abcam) binds both 
unphosphorylated and Ser2- and Ser5 –phosphorylated forms of the heptapeptide repeat YSPTSPS 
within the CTD of RNA Pol II. Using antibodies specifically recognizing phosphorylated Ser2 or 
Ser5 of RNA Pol II for ChIP experiments it is feasible to distinguish between initiating and 
terminating polymerase. To test whether the FET proteins have an influence on transcription, FET 
proteins were depleted and ChIP followed by qRT-PCR was performed. Cells were treated with 
FUS, EWSR1 and TAF15 siRNAs to knockdown expression of all three FET proteins (triple 
knockdown) or left untreated (mock). After ChIP the immunoprecipitated DNA was analyzed by 
qRT-PCR using primer specific for the SRSF3 locus and further downstream (Fig.17). 
Triple knockdown of FET proteins resulted in an increase of RNA Pol II at the TSS of SRSF3 
simultaneously with a slight increase of Ser2- and Ser5-phosphorylated RNA Pol II forms. At the 
end of the SRSF3 gene and further downstream the amount of polymerase decreases whereas Ser2- 
and Ser5- phosphorylated forms remain nearly similar after knockdown. Consistently, Schwartz et 
al. also showed an increase of total RNA Pol II near TSSs but in contrast to our data they also 
showed a significant increase of Ser2 phosphorylation around TSSs. This indicates that loss of the 
FET proteins leads to an accumulation of RNA Pol II at the TSS and a decrease at the end of the 
gene. In the case of SRSF3, changes in the phosphorylation state of RNA Pol II CTD do not seem to 
be the reason for the altered expression of the longer SRSF3 mRNA isoform as verified by qRT-
PCR after FET protein depletion.  
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Fig. 17: Loss of FET proteins alters distribution of RNA polymerase II around SRSF3. 
Various regions around the SRSF3 gene were tested for RNA Pol II occupancy using ChIP. Antibodies recognizing both 
unphosphorylated and phosphorylated Ser5 residues of the RNA Pol II (Pol II Ab), recognizing only phosphorylated 
Ser2 (Pol II S2 Ab) and recognizing only phosphorylated Ser5 residues (Pol II S5 Ab) were used for 
immunoprecipitation. Mouse IgG and rabbit IgG were used as negative controls for unspecific binding. The 
immunoprecipitated DNA was quantified by qRT-PCR. Error bars represent the standard deviation for three technical 
replicates. 
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3.9 FET proteins bind antisense, non-coding RNAs at promoter regions 
Since RBPs can interact with different classes of RNAs (Cabili et al. 2011), binding of the FET 
proteins to long intergenic non-coding RNAs (lincRNAs) was examined as well. About 1% of the 
FUS and EWSR1 and 0.5% of the TAF15 sequence clusters mapped to ncRNAs, supporting 
previous findings that the FET proteins interact with the promoter ncRNACCND1 which negatively 
regulates transcription of CCND1 in cis by forming a ribonucleoprotein repressor complex (Wang 
et al. 2008). To investigate whether FET proteins have a more widespread function in the regulation 
of cell growth by associating with ncRNAs derived from promoters of cell cycle regulators, 216 
transcribed regions that encode putative ncRNAs within promoters of 49 human cell-cycle genes 
(cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors) were scanned for 
possible binding sites. In 10 of the 49 genetic loci FUS, EWSR1 and TAF15 sequence clusters 
mapped to ncRNAs (Tab.3). Interaction with this subset of promoter ncRNA seemed to be specific 
to FET proteins. TARDBP, although described to bind to several ncRNAs (Tollervey et al. 2011), 
and the FUS variant R495X, yielded no sequence clusters mapping to these genomic regions 
(Fig.18). In particular for FUS it has been already shown that it is often bound to RNA antisense 
upstream of promoter regions leading to a down regulation of transcription of the sense strand 
(Ishigaki et al. 2012). EWSR1 and TAF15 PAR-CLIP data revealed RNA binding sites antisense to 
promoters of genes involved in cell cycle regulation (Fig.18). These findings suggest that FUS, 
EWSR1 and TAF15 might have a specific and more pervasive function, mediated by promoter 
ncRNAs, in transcriptional regulation of cell cycle genes. 
55 
 
 Results  
 
A 
B 
56 
 
 Results  
Fig. 18: Representative examples of FET protein binding to intergenic regions in the proximity of promoter 
regions. 
RNA-Seq coverage of FUS, EWSR1 and TAF15 siRNA transfected cells (Triple KD) and untransfected cells (Mock) is 
shown together with FUS, EWSR1, TAF15 and TARDBP sense (blue) and antisense binding sites (red) determined by 
PAR-CLIP around  CCND2 (A) and CDKN3 (B). Furthermore protein occupancy profiling data on mRNA (Baltz et al. 
2012) with sequence coverage in orange and T-C transition profile in black is given together with the UCSC PhastCons 
conservation of placental mammals in green.  
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Tab. 3: FET binding sites at transcripts derived from promoter regions of cell cycle genes 
Gene name Chromosome FUS cluster EWSR1 cluster TAF15 cluster 
CDKL5 chrX - - - 
CCNB3 chrX - - - 
CDKN2A chr9 - - - 
ARF chr9 - + - 
CDKN2B chr9 + - - 
CDK9 chr9 - - - 
CCNE2 chr8 - + - 
CDK6 chr7 - - - 
CDK5 chr7 - + - 
CDKN1A chr6 - + - 
CCND3 chr6 - - - 
CCNC chr6 - + - 
CCNO chr5 - - - 
CDKL3 chr5 - - - 
CCNJL chr5 - - - 
CCNG1 chr5 - - - 
CCNI chr4 - - - 
CCNG2 chr4 - - - 
CCNA2 chr4 - - - 
CCNL1 chr3 - - - 
CDKL4 chr2 - - - 
CNNM4 chr2 - - - 
CNNM3 chr2 - - - 
CCNT2 chr2 - - - 
CCNYL1 chr2 - - - 
CDK5R2 chr2 - - - 
CDKN2D chr19 - - - 
CCNE1 chr19 - - - 
CDK5R1 chr17 + + + 
CDK3 chr17 - - - 
CCNF chr16 - - - 
CDK3 chr17 - - - 
CCNF chr16 - - - 
CCNYL3 chr16 - - - 
CDK10 chr16 - - - 
CCNB2 chr15 - - - 
CDKN3 chr14 - - - 
CCNK chr14 - + - 
CDK8 chr13 - - - 
CCNA1 chr13 - - - 
CCND2 chr12 - + + 
CDKN1B chr12 - - - 
CCNT1 chr12 - - - 
CDK2 chr12 - - - 
CDK4 chr12 - - - 
CDKN1C chr11 - - - 
CCND1 chr11 - - - 
CCNYL2 chr10 - - - 
CNNM1 chr10 - - - 
CCNL2 chr1 - - - 
CDKN2C chr1 + - - 
List of cell cycle genes whith putative ncRNA expression at their promoters and presence (+) or 
absence (-) of FET binding sites. 
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3.10 FET proteins modulate miRNA expression 
RBPs are key components in the determination of miRNA function as they control different stages 
of miRNA biogenesis, localization and activity. In particular, FET proteins were implicated to be 
involved in miRNA biogenesis based on their presence in the microprocessor, the Drosha-
containing protein complex catalyzing the first step in miRNA maturation (Gregory et al. 2004). 
Furthermore, FUS contributes to biogenesis of a subset of miRNAs involved in neuronal function 
and differentiation (Morlando et al. 2012). Also TAF15 regulates gene expression of cell cycle 
regulatory genes post-transcriptional through a pathway involving miRNAs (Ballarino et al. 2012). 
Since FET protein sequence clusters mapped to several pre-miRNA precursors (Fig.19A), the effect 
of FUS, EWSR1 and TAF15 on miRNA expression was investigated by sequencing small RNA 
libraries from mock- and siRNA-transfected cells. A comparison of the small RNA libraries 
revealed only mild changes in miRNA expression upon RNAi-mediated protein knockdown for the 
single FET proteins (Supplementary Tab.1). Quantitative RT-PCR on a selected number of miRNAs 
confirmed these findings (Fig.19B). Upon FUS knockdown expression of miR-10a is decreased 
whereas expression of miR-19a, miR-92a and miR-148 does not change. Interestingly, triple 
knockdown of all three FET proteins at the same time lead to downregulation of miR-19a, miR-92a, 
miR-10a and miR148a. This indicates some degree of redundancy of FET proteins.  
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Fig. 19: Effects on miRNA expression after depletion of FET proteins. 
(A) Distribution of FET clusters around the U24 locus and several miRNA cluster. (B) Upon FUS knockdown, miRNA 
abundance did not change. Total RNA of siRNA- and mock-transfected cells was subjected to TaqMan qRT-PCR and 
expression of U6 (control), miR-19a, miR-92a, miR10a and miR148a was normalized to the expression of the 
endogenous control U24 snRNA. 
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4. Discussion 
RBPs are playing an important role in posttranscriptional gene regulation. However, the function of 
many RBPs is still unknown. One family of such RBPs constitute FUS/TLS, EWSR1 and TAF15 
which are multifunctional proteins involved in several cancer types like sarcomas, leukemias but 
also in neurodegenerative diseases including ALS and FTLD. Nevertheless, despite emerging 
information of FET protein functions many aspect of their involvement in gene regulation are 
elusive. The main goal of this study was to elucidate the role of the FET family members in 
transcriptional and posttranscriptional gene regulation. 
4.1 FET proteins bind mainly intronic sequences 
To determine the transcriptome wide binding sites for FUS, EWSR1 and TAF15 at a nucleotide 
resolution PAR-CLIP was used. FET proteins bind mostly to introns, consistent with the nuclear 
localization of the proteins (Andersson et al. 2008), but also to 3’UTRs and CDS (Fig.7). For 
TAF15, besides intronic binding also a larger set of binding sites were located in 3’UTRs. This 
supports the idea that these proteins might still bind to different targets or have different binding 
sites within the same target, respectively, despite the high identity in their RNA binding domain. 
However, intersection of the top 1000 targets ranked by T-to-C frequency revealed a large overlap 
of targets in general (Fig.9). This in accordance with the study by Hoell and coworkers where it was 
shown that also the binding sites within the RNA targets largely overlap between all three FET 
family members (Hoell et al. 2011).  
For FUS and TAF15 a clear preference to UAC rich regions was seen, whereas EWSR1 seem to 
bind more GC-rich sequences surprisingly (Fig.10). The different binding motif of EWSR1 
indicates binding of different targets or target sites then FUS and TAF15 respectively. This is 
consistent with the observation that among the top 1000 target RNAs of each FET protein, ranked 
by the number of binding sites, EWSR1 shows the smallest overlap (Fig.9). This might point to less 
redundancy between all three FET proteins as initially assumed. Due to the different binding motif 
of EWSR1 it would be conceivable that FUS and TAF15 might exhibit some redundancy. 
Next, binding specificity of all three proteins has to be verified for example by electrophoretic 
mobility shift assay (EMSA).  In contrast to this study, Hoell et al. did not reveal any specific 
binding motif of FUS, EWSR1 and TAF15 by PAR-CLIP in HEK293 cells (Hoell et al. 2011).  
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They also reported that secondary structure of the RNA might play an important role in recognition 
suggesting FUS binding to AU-rich RNA stem loop structures. By contrast, motif analysis of the 
FET PAR-CLIP data confirmed a preference for binding single-stranded sequences for all three FET 
proteins (Fig.10). There is no indication of preferential binding to stem loop RNA structures as 
suggested by Hoell et al. 
Comparison with the TARDBP PAR-CLIP data revealed no indication for a similar binding motif of 
FUS and TARDBP suggesting a difference in target binding.  
In general, the large number of RNA binding sites for all three FET proteins implies that these 
proteins tend to bind RNA frequently which would support a general role of FET proteins in mRNA 
processing. Non-physiological binding of overexpressed recombinant protein might be also a reason 
for the large number of binding sites. However, expression levels of recombinant FET proteins 
were even slightly lower than the expression levels of the endogenous proteins (Fig.5)  
The ALS causing FUS mutant R495X showed reduced binding to introns and an enhanced binding 
to 3’ and 5’UTRs presumably due to its altered cytoplasmic localization (Fig.7). It would be 
conceivable that the FUS mutant bind different targets as a result of the altered localization. This 
supports the model where ALS is caused by a combination of a loss of function and a gain of 
toxicity. On the one hand mutant FUS is mainly localized in the cytoplasm and aggregates in 
ubiquitin-positive inclusions because of a disrupted putative nuclear localization signal at the C-
terminus and cannot function fully in the nucleus anymore. On the other hand in the cytoplasm FUS 
R495X can access different targets leading to a gain of function effect. Both scenarios support the 
assumption that misregulated RNA processing could trigger neurodegeneration.  
However, a recent study by Shelkovnikova et al. indicated that FUS aggregation itself can trigger 
ALS-like pathology (Shelkovnikova et al. 2013). They could show that a truncated version of FUS 
with a disrupted NLS and RNA binding motif already aggregates in SH-SY5Y neuroblastoma cells 
but become excluded from stress granules. However, RNA-binding competent variants are recruited 
to stress granules. Transgenic mice expressing the RNA-binding incompetent FUS variant develop 
fatal motor neuron pathology and endogenous FUS is present in pathological inclusions formed by 
transgenic truncated protein.  
Recently, two studies focussed on RNA granule-like structures which are often composed of RBPs 
containing low-complexity (LC) sequences (Han et al. 2012; Kato et al. 2012). LC sequences are 
protein regions with little diversity in their amino acid composition, often found in RNA- and 
DNA-binding proteins (Michelitsch and Weissman 2000). These sequences are also present in the 
N-terminal end of FUS, EWSR1 and TAF15. The LC sequences of these proteins associated with 
other RBPs can be reversibly transformed from soluble to polymeric, amyloid-like fibers. 
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 Kato et al. proposed that this transition may help RBPs to move in and out of cellular structures 
like RNA granules, stress granules and P bodies (Kato et al. 2012). The amyloid-like fibers are able 
to recruit and retain mRNAs entering neuronal granules similar to RNA granules. Therefore, LC 
sequences may be responsible for forming pathological aggregates. Interestingly, phosphorylation 
of the LC domain of FUS prevented retention of these mRNAs (Han et al. 2012). Hence, the 
dynamics of aggregation and disaggregation might be regulated by posttranslational modifications.  
In conclusion, it is feasible that alterations in RNA metabolism may not be the primary cause in 
ALS but rather be a “second hit” that contributes to irreversible aggregation of FUS. 
 
4.2 FET protein and TARDBP mRNA targets encode proteins involved in protein 
degradation 
Interestingly, analyzing the RNA targets of all three FET proteins as well as TARDBP, ubiquitin-
proteasome-related gene categories are overrepresented (Fig.9). There are several lines of evidence 
that an impairment of protein turnover contribute to the pathogenesis of ALS and other 
neurodegenerative diseases. Mutations in UBQLN2, which encodes the ubiquitin-like protein 
ubiquilin 2, were shown to cause dominantly inherited ALS (Deng et al. 2011). UBQLN2 is a 
member of the ubiquitin-like protein family (ubiquilins), which regulates the ubiquitin–proteasome 
system (UPS) of protein degradation by delivering ubiquitinated proteins to the proteasome. Using 
an UPS reporter substrate, the investigators could prove a significantly slower degradation of the 
substrate in cells expressing mutant ubiquilin 2 than in cells expressing the wildtype protein. 
Furthermore, ubiquilin positive inclusions are common in a wide spectrum of ALS. Whether 
ubiquilin 2 inclusions initiate neurodegeneration or are a consequence of intracellular deregulation 
remains to be established.  
ALS linked-mutations were also identified in other genes affecting protein homeostasis. Mutations 
in optineurin (OPTN), a multifunctional protein which is able to bind polyubiquitinated proteins, 
have been reported in sporadic and familial ALS cases (Maruyama et al. 2010; Del Bo et al. 2011) 
In addition, mutations in VCP were identified in 1-2 % of all familial ALS cases (Johnson et al. 
2010). The ATP-driven chaperone valosin-containing protein (VCP) interacts with a wide range of 
ubiquitinated proteins to enable degradation and regulates critical steps in ubiquitin-dependent 
protein quality control (Meyer et al. 2012).  
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Similar to VCP, p62/SQSTM1 has been shown to interact with polyubiquitinated proteins targeting 
them to the proteasome (Moscat and Diaz-Meco 2012). p62 inclusions have been reported in many 
neurodegenerative diseases and mutations in p62 have been found in both familial and sporadic 
ALS patients (Fecto et al. 2011; Brettschneider et al. 2012; Rubino et al. 2012; Teyssou et al. 2013).  
Although, how all these ALS-associated mutations in OPTN, VCP, p62, TARDBP and FUS 
contribute to the pathogenesis of ALS has not been established yet, proteasome disturbance seems 
likely to play an important role. 
4.3 FET protein binding leads to increase in target mRNA levels 
Based on the RNA-Seq data of FET down-regulated cells, a stabilizing function of target transcripts 
was observed (Fig.13). siRNA mediated knockdown of FUS, EWSR1 and TAF15 led to highly 
significant destabilization of transcripts with FET binding sites which confirms the functionality of 
the targets. The exact mechanisms by which the FET proteins achieve this mRNA stabilization still 
need to be revealed. Since the majority of FET binding sites lie within introns it would be 
conceivable that FET proteins play an important role in pre-mRNA processing, especially splicing. 
If splicing of target mRNAs is disturbed upon FET protein depletion, pre-mRNAs might be 
degraded.  
We also quantified the protein abundance using the SILAC approach (Ong et al. 2002) and 
compared target protein levels in mock transfected cells versus FUS, EWSR1 and TAF15 siRNA 
transfected cells. The cumulative distribution in protein abundance of targeted proteins did not 
change in statistically significant manner (data not shown). A recent study of FET protein targets 
also based on PAR-CLIP did not observe FET-target dependent mRNA changes, despite their use of 
a similar cell system (Hoell et al. 2011). Global changes in protein abundance of 700 to 1100 
proteins expressed from FET-targeted mRNAs detected were relatively small (data not shown). 
However, using the SILAC approach it is only possible to measure changes in protein abundance 
between siRNA- and mock-transfected cells. On the other hand using pulsed SILAC (pSILAC) it is 
possible to assess an involvement of FET proteins in protein synthesis (Schwanhausser et al. 2009). 
To assess the influence of FUS on translation, FUS knockdown under pSILAC conditions was 
performed. Changes in protein expression from FUS-targeted mRNAs were relatively small (data 
not shown), indicating that at least FUS on its own is not acting as global translational regulator. 
65 
 
 Discussion  
4.4 FET proteins are involved in alternative splicing regulation 
Looking further into the detailed context of binding site distribution within introns, an enriched 
binding for all three FET proteins upstream of 3’splice sites could be observed (Fig.14). This is in 
line with the assumption that these proteins are involved in pre-mRNA splicing regulation. FUS and 
EWSR1 were already identified in the same RNA-splicing complex together with polypyrimidine-
tract-binding-associated factor (PSF) (Deloulme et al. 1997) and all three proteins were reported to 
be part of the spliceosomal complex (Rappsilber et al. 2002). Moreover, FUS interacts with 
different splicing factors like serine/arginine-rich (SR) proteins (Yang et al. 1998). Knockdown of 
FUS and EWSR1 in HEK293 cells affected splicing of ENAH, THAP6, CSNK1D and PDE8A, 
respectively (Fig.15). The effect on alternative splicing of target RNAs regulated by FUS and 
EWSR1 seems to be transcript-specific since exon skipping is both up and down regulated upon 
FUS and EWSR1 knockdown. Whether FET proteins regulate splicing of target pre-mRNAs 
directly or just indirectly by recruiting other splicing factors to target mRNAs is not known yet.  
Recent reports show similar effects in mouse brain (Lagier-Tourenne et al. 2012; Rogelj et al. 
2012). Both studies demonstrated a saw-tooth like binding pattern for FUS in long genes indicating 
that FUS remains bound to pre-mRNAs until splicing is completed. Furthermore, they did not 
observe any significant overlap with exons regulated by FUS and TARDBP but both proteins 
regulate splicing of mRNAs derived from genes involved in neuronal development. 
Interestingly, the FUS R495X mutant has less intronic targets due to their cytoplasmic localization 
and above all less binding sites around splice sites (Fig.7). It is suggested that aberrations of RNA 
metabolism are important factors in the pathogenesis of ALS and FTLD. It is feasible that 
aberrantly spliced mRNAs could contribute to the development of ALS. Multiple abnormal mRNAs 
of the astroglial glutamate transporter protein EAAT2 have been identified in many ALS patients. 
Proteins translated from these aberrant mRNAs are rapidly degraded and have a dominant negative 
effect on the wildtype protein leading to a loss of EAAT2 (Lin et al. 1998). EAAT2 deficiency 
leads to increased extracellular glutamate and neuronal degeneration in motor cortex and spinal 
cord. Another study also identified aberrantly spliced cell adhesion genes in sporadic ALS patients 
and some of them could be directly related to TARDBP misregulation (Rabin et al. 2010; Xiao et al. 
2011). It may be that FUS performs similar interactions and that disturbance of this function could 
be linked to ALS.  
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4.5 FUS and EWSR1 affect mRNA expression of the SRSF3 locus 
It was proposed that the FET family is likely to be involved in regulating transcription by direct 
interaction with RNA Pol II and TFIID (Bertolotti et al. 1996). In this study, transcriptional 
regulation by the FET family was investigated using the example of the SRSF3 region. FUS- and 
EWSR1-specific binding sites were found downstream of the 3’ end of the SRFS3 transcript 
(Fig.16). High level of protein binding to this region in general is further supported by protein 
occupancy profiling (Baltz et al. 2012). In addition RNA-Seq coverage and validation by PCR (data 
not shown) support existence of such long transcript derived from the SRFS3 locus which is likely 
to be a read-through transcript variant of this gene. It is feasible that FUS and EWSR1 regulate 
transcription of SRFS3 by interaction with RNA Pol II subunits and their bound mRNA. This is 
supported by the finding that knockdown of FET proteins leads to an upregulation of the SRSF3 
extended transcript (Fig.16). Whether this is a direct effect of FET protein depletion or just an off-
target effect has to be investigated further for example by performing another knockdown using a 
different set of siRNAs. A recent publication analyzing the genome-wide localization of FUS on the 
chromatin of HEK293 cells showed an enrichment of FUS at the TSS and an accumulation of RNA 
Pol II at the TSS upon loss of FUS (Schwartz et al. 2012).  Analysis of RNA Pol II occupancy upon 
triple knockdown around the SRSF3 gene in this study confirmed these findings (Fig.17). 
Furthermore, RNA Pol II occupancy decreased at the SRSF3 3’UTR and further downstream upon 
FET protein depletion. This is contradictory to the qPCR data after knockdown where the SRSF3 
extended transcript is upregulated (Fig.16). Since FET proteins are involved in alternative splicing 
regulation, it is conceivable that FET protein knockdown induces an isoform switch of SRSF3 
producing rather longer than short SRSF3 transcripts. This needs be verified for example by RT-
PCR analysis of SRSF3 isoform expression or in vitro splicing assays. In addition, we tested 
whether changes in distribution of RNA Pol II were accompanied by changes in Ser2 or Ser5 
phosphorylation of the RNA Pol II CTD. In contrast to Schwartz et al., we did not detect any 
significant changes in Ser2 or Ser5 phosphorylation of RNA Pol II CTD around the SRSF3 locus 
upon FET protein knockdown (Fig.17). Schwartz et al. showed that RNA binding nucleates the 
formation of high-order FUS assemblies which bind the RNA Pol II CTD (Schwartz et al. 2013). 
Both the LC domain and RGG domain of FUS contribute to the assembly. The authors suggest that 
the FUS assemblies influence transcription by forming a protein scaffold that recruits RNA Pol II. 
Another study provided direct evidence that FUS assemblies can stimulate transcription (Kwon et 
al. 2013). Kwon et al. showed that polymeric fibers formed from the LC domain of FUS, EWSR1 
and TAF15 are able bind the RNA Pol II CTD directly.  
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Phosphorylation of the CTD facilitates the release of the RNA Pol II from the FET LC domain 
polymer. The authors speculate that the native FET proteins might bind to ncRNAs that remain 
nascently attached to the DNA bringing these complexes in close proximity to target genes. The 
locally elevated FET protein concentration might facilitate LC domain polymerization necessary to 
recruit RNA Pol II.  
Furthermore, it would be conceivable that FET proteins link mRNA 3’ end processing and 
transcriptional elongation and termination. The connection between polyadenylation and 
transcriptional termination was established some time ago discovering that both processes are 
dependent on the same DNA sequences at 3’ ends of genes (Connelly and Manley 1988). Forming 
the 3’ end of a transcript generated by RNA Pol II is a multistep process where the 3’ end must be 
generated by combination of cleavage and polyadenylation. The elongating RNA Pol II complex 
must be halted and the Pol II enzyme terminated to allow for recycling back to transcriptional 
initiation (Proudfoot et al. 2002). A strong connection has been made between the phosphorylation 
of the RNA Pol II CTD and recruitment of polyadenylation factors. For example, the 
polyadenylation factor Ssu72 for has been shown to have CTD phosphatase activity 
(Krishnamurthy et al. 2004) raising the possibility that some polyadenylation factors can influence 
phosphorylation of the CTD to facilitate recycling of the RNA Pol II to a form competent for 
transcription initiation. Other factors like the FET proteins might also affect directly or indirectly 
the amount of RNA PoI II at genes thereby regulating the 3’end formation of transcripts.  
In conclusion, our data suggest that the FET proteins modulate the total RNA Pol II level at the TSS 
as well as at the end of the SRSF3 gene but not the phosphorylation state of the CTD. It would be 
crucial to investigate RNA Pol II occupancy and CTD phosphorylation on more genomic loci 
bound by the FET proteins. 
 
4.6 FET proteins are involved in regulation of non-coding RNAs 
ncRNAs are involved in many cellular processes and important posttranscriptional regulators of 
gene expression. This regulation can occur in cis or trans. Promoter-associated ncRNAs are a group 
of ncRNAs which can act in cis. These transcripts are expressed near transcription start sites or 
from upstream elements of the promoter. Transcription occurs in both sense and antisense direction 
with respect to the downstream gene. Most of them are associated with highly expressed genes 
whereas themselves being only weakly expressed and highly unstable (Preker et al. 2008).  
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There are several evidences connecting promoter-associated ncRNAs with transcriptional activation 
and repression. siRNA-directed transcriptional activation of p21 gene expression was demonstrated 
to be the result of post-transcriptional silencing of a p21-specific antisense transcript (Morris et al. 
2008). Expression of ncRNAs derived from the cyclin D1 (CCND1) promoter is induced upon DNA 
damage (Wang et al. 2008). Binding of these ncRNAs to the 5’ regulatory region of the cyclin D1 
gene also recruits FUS to that locus. Upon binding these ncRNAs, FUS changes its allosteric 
conformation and specifically binds to the CREB-binding protein (CBP) and p300 thus inhibiting 
their histone acetyltransferase activity and repressing CCND1 expression. Similarly, EWSR1 and 
TAF15 were found to bind CBP and p300 and exerted inhibitory effects. We analyzed our FET 
PAR-CLIP data in combination with RNA-Seq data to find more evidences for this type of 
transcriptional regulation involving promoter-associated ncRNAs (Fig.18). Multiple putative 
ncRNAs with FET binding sites in the vicinity of cell cycle promoters were found (Tab.3). This 
indicates that FET proteins might have a functional role in transcription of cell cycle regulators by 
being recruited to their loci through gene-specific ncRNAs.  
Another group of ncRNAs which act in trans are miRNAs which mainly down-regulate expression 
of target genes. FUS, EWSR1 and TAF15 were already implicated in the regulation miRNA 
biogenesis, since all three proteins were identified in the same complex with Drosha (Gregory et al. 
2004). Our PAR-CLIP results strengthen this assumption as FET proteins have binding sites in 
several pri-miRNAs (Fig.19Fig. 19).  
Knockdown of FUS alone does not seem to have an influence on miRNA expression whereas 
depletion of all three proteins simultaneously leads to a down regulation of selected miRNAs. This 
is in agreement with a recent publication where TAF15 depletion lead to decreased pri-miR-17-5p 
and pri-miR-20a level thereby regulating gene expression of cell cycle regulatory genes (Ballarino 
et al. 2012). Furthermore, this study showed that expression of Drosha and DGCR8 was unaffected 
by TAF15 siRNA transfection indicating that this is not an unspecific effect due to a destabilized 
microprocessor complex. Further work is needed to elucidate whether EWSR1 also participates in 
the regulation of miRNA biogenesis and if FET proteins maybe work together in the regulation of 
miRNA processing. Moreover, it would be interesting to look at which step FET proteins regulate 
miRNA biogenesis. This could be done for instance by quantification of the different precursor 
miRNA levels using qRT-PCR in FET-depleted cells. Another possibility is that the down 
regulation of miRNA expression is an unspecific effect since the Drosha complex gets destabilized 
upon FET depletion. 
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4.7 Conclusion and outlook 
In this study, the role of FET protein members in transcriptional and posttranscriptional gene 
regulation in comparison with the ALS-related proteins TARDBP and FUS R495X was examined. 
PAR-CLIP was used to determine the RNA targets of the FET proteins and discovered preferential 
binding in introns especially near splice sites. Regulation of splicing by FUS and EWSR1 could be 
verified. Interestingly, the FUS mutant R495X showed reduced binding to splice sites raising the 
possibility that splicing regulation might be dysregulated in ALS and thus contributing to the 
pathomechanism.  Comparison of FUS and TARDBP RNA targets revealed an overrepresentation of 
ubiquitin-proteasome-related transcripts which confirms the theory that defects in the protein 
degradation pathway might be involved in the development of ALS. By using reporter assays 
targeting different points along the ubiquitin-mediated proteolysis pathway in FUS and TARDBP 
knockdown cells it will be possible to monitor at which step this pathway might be disordered. 
Furthermore, by depletion of FUS, EWSR1 and TAF15 it was discovered that FET proteins have 
stabilizing function of their target RNAs. In addition, FET proteins probably participate in 
transcriptional regulation on the one hand by interaction with promoter-associated ncRNAs and on 
the other hand by interaction with RNA Pol II. It would be feasible that FET proteins are connecting 
transcription and splicing by being recruited to transcribed genes, influencing transcription and 
remain bound during transcriptional elongation until splicing is completed. Thereby, FET proteins 
can regulate gene expression of targets at different levels.     
Considering the many physiological functions of FUS, EWSR1 and TAF15 in the cell, loss of one 
or all three proteins due to mutations can alter various cellular processes and have detrimental 
consequences. Further analysis of FUS and FUS R495X RNA targets will hopefully shed more light 
in the pathogenesis of ALS and give first starting point in therapy of this severe disease. 
 
70 
 
 References  
References 
Aasland R, Gibson TJ, Stewart AF. 1995. The PHD finger: implications for chromatin-mediated 
transcriptional regulation. Trends in biochemical sciences 20: 56-59. 
Anderson P, Kedersha N. 2008. Stress granules: the Tao of RNA triage. Trends in biochemical 
sciences 33: 141-150. 
Andersson MK, Stahlberg A, Arvidsson Y, Olofsson A, Semb H, Stenman G, Nilsson O, Aman P. 
2008. The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-
specific expression patterns and involvement in cell spreading and stress response. BMC cell 
biology 9: 37. 
Auweter SD, Oberstrass FC, Allain FH. 2006. Sequence-specific binding of single-stranded RNA: 
is there a code for recognition? Nucleic acids research 34: 4943-4959. 
Backe PH, Messias AC, Ravelli RB, Sattler M, Cusack S. 2005. X-ray crystallographic and NMR 
studies of the third KH domain of hnRNP K in complex with single-stranded nucleic acids. 
Structure 13: 1055-1067. 
Baechtold H, Kuroda M, Sok J, Ron D, Lopez BS, Akhmedov AT. 1999. Human 75-kDa DNA-
pairing protein is identical to the pro-oncoprotein TLS/FUS and is able to promote D-loop 
formation. The Journal of biological chemistry 274: 34337-34342. 
Ballarino M, Jobert L, Dembele D, de la Grange P, Auboeuf D, Tora L. 2012. TAF15 is important 
for cellular proliferation and regulates the expression of a subset of cell cycle genes through 
miRNAs. Oncogene. 
Baltz AG, Munschauer M, Schwanhausser B, Vasile A, Murakawa Y, Schueler M, Youngs N, 
Penfold-Brown D, Drew K, Milek M et al. 2012. The mRNA-bound proteome and its global 
occupancy profile on protein-coding transcripts. Molecular cell 46: 674-690. 
Bertolotti A, Bell B, Tora L. 1999. The N-terminal domain of human TAFII68 displays 
transactivation and oncogenic properties. Oncogene 18: 8000-8010. 
Bertolotti A, Lutz Y, Heard DJ, Chambon P, Tora L. 1996. hTAF(II)68, a novel RNA/ssDNA-
binding protein with homology to the pro-oncoproteins TLS/FUS and EWS is associated 
with both TFIID and RNA polymerase II. The EMBO journal 15: 5022-5031. 
Bertolotti A, Melot T, Acker J, Vigneron M, Delattre O, Tora L. 1998. EWS, but not EWS-FLI-1, is 
associated with both TFIID and RNA polymerase II: interactions between two members of 
the TET family, EWS and hTAFII68, and subunits of TFIID and RNA polymerase II 
complexes. Molecular and cellular biology 18: 1489-1497. 
Bertrand P, Akhmedov AT, Delacote F, Durrbach A, Lopez BS. 1999. Human POMp75 is identified 
as the pro-oncoprotein TLS/FUS: both POMp75 and POMp100 DNA homologous pairing 
activities are associated to cell proliferation. Oncogene 18: 4515-4521. 
71 
 
 References  
Bosco DA, Lemay N, Ko HK, Zhou H, Burke C, Kwiatkowski TJ, Jr., Sapp P, McKenna-Yasek D, 
Brown RH, Jr., Hayward LJ. 2010. Mutant FUS proteins that cause amyotrophic lateral 
sclerosis incorporate into stress granules. Human molecular genetics 19: 4160-4175. 
Brettschneider J, Van Deerlin VM, Robinson JL, Kwong L, Lee EB, Ali YO, Safren N, Monteiro 
MJ, Toledo JB, Elman L et al. 2012. Pattern of ubiquilin pathology in ALS and FTLD 
indicates presence of C9ORF72 hexanucleotide expansion. Acta neuropathologica 123: 825-
839. 
Buratti E, Baralle FE. 2004. Influence of RNA secondary structure on the pre-mRNA splicing 
process. Molecular and cellular biology 24: 10505-10514. 
Buratti E, Brindisi A, Giombi M, Tisminetzky S, Ayala YM, Baralle FE. 2005. TDP-43 binds 
heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important 
region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 
splicing. The Journal of biological chemistry 280: 37572-37584. 
Burd CG, Dreyfuss G. 1994. Conserved structures and diversity of functions of RNA-binding 
proteins. Science 265: 615-621. 
Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A, Rinn JL. 2011. Integrative 
annotation of human large intergenic noncoding RNAs reveals global properties and specific 
subclasses. Genes Dev 25: 1915-1927. 
Calvio C, Neubauer G, Mann M, Lamond AI. 1995. Identification of hnRNP P2 as TLS/FUS using 
electrospray mass spectrometry. Rna 1: 724-733. 
Castello A, Fischer B, Eichelbaum K, Horos R, Beckmann BM, Strein C, Davey NE, Humphreys 
DT, Preiss T, Steinmetz LM et al. 2012. Insights into RNA biology from an atlas of 
mammalian mRNA-binding proteins. Cell 149: 1393-1406. 
Chang KY, Ramos A. 2005. The double-stranded RNA-binding motif, a versatile macromolecular 
docking platform. The FEBS journal 272: 2109-2117. 
Chansky HA, Hu M, Hickstein DD, Yang L. 2001. Oncogenic TLS/ERG and EWS/Fli-1 fusion 
proteins inhibit RNA splicing mediated by YB-1 protein. Cancer research 61: 3586-3590. 
Couthouis J, Hart MP, Erion R, King OD, Diaz Z, Nakaya T, Ibrahim F, Kim HJ, Mojsilovic-
Petrovic J, Panossian S et al. 2012. Evaluating the role of the FUS/TLS-related gene 
EWSR1 in amyotrophic lateral sclerosis. Human molecular genetics 21: 2899-2911. 
Couthouis J, Hart MP, Shorter J, DeJesus-Hernandez M, Erion R, Oristano R, Liu AX, Ramos D, 
Jethava N, Hosangadi D et al. 2011. A yeast functional screen predicts new candidate ALS 
disease genes. Proceedings of the National Academy of Sciences of the United States of 
America 108: 20881-20890. 
Crozat A, Aman P, Mandahl N, Ron D. 1993. Fusion of CHOP to a novel RNA-binding protein in 
human myxoid liposarcoma. Nature 363: 640-644. 
Daigle JG, Lanson NA, Jr., Smith RB, Casci I, Maltare A, Monaghan J, Nichols CD, Kryndushkin 
D, Shewmaker F, Pandey UB. 2013. RNA-binding ability of FUS regulates 
72 
 
 References  
neurodegeneration, cytoplasmic mislocalization and incorporation into stress granules 
associated with FUS carrying ALS-linked mutations. Human molecular genetics 22: 1193-
1205. 
de Hoog CL, Foster LJ, Mann M. 2004. RNA and RNA binding proteins participate in early stages 
of cell spreading through spreading initiation centers. Cell 117: 649-662. 
de Lima Morais DA, Fang H, Rackham OJ, Wilson D, Pethica R, Chothia C, Gough J. 2011. 
SUPERFAMILY 1.75 including a domain-centric gene ontology method. Nucleic acids 
research 39: D427-434. 
Del Bo R, Tiloca C, Pensato V, Corrado L, Ratti A, Ticozzi N, Corti S, Castellotti B, Mazzini L, 
Soraru G et al. 2011. Novel optineurin mutations in patients with familial and sporadic 
amyotrophic lateral sclerosis. Journal of neurology, neurosurgery, and psychiatry 82: 1239-
1243. 
Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, 
Rouleau G et al. 1992. Gene fusion with an ETS DNA-binding domain caused by 
chromosome translocation in human tumours. Nature 359: 162-165. 
Deloulme JC, Prichard L, Delattre O, Storm DR. 1997. The prooncoprotein EWS binds calmodulin 
and is phosphorylated by protein kinase C through an IQ domain. The Journal of biological 
chemistry 272: 27369-27377. 
Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, Siddique N, Yang Y, Fecto F, Shi Y, Zhai H 
et al. 2011. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS 
and ALS/dementia. Nature 477: 211-215. 
Dormann D, Rodde R, Edbauer D, Bentmann E, Fischer I, Hruscha A, Than ME, Mackenzie IR, 
Capell A, Schmid B et al. 2010. ALS-associated fused in sarcoma (FUS) mutations disrupt 
Transportin-mediated nuclear import. The EMBO journal 29: 2841-2857. 
Dreyfuss G, Kim VN, Kataoka N. 2002. Messenger-RNA-binding proteins and the messages they 
carry. Nature reviews Molecular cell biology 3: 195-205. 
Fecto F, Yan J, Vemula SP, Liu E, Yang Y, Chen W, Zheng JG, Shi Y, Siddique N, Arrat H et al. 
2011. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Archives of 
neurology 68: 1440-1446. 
Fitzgerald KD, Semler BL. 2011. Re-localization of cellular protein SRp20 during poliovirus 
infection: bridging a viral IRES to the host cell translation apparatus. PLoS pathogens 7: 
e1002127. 
Fujii R, Okabe S, Urushido T, Inoue K, Yoshimura A, Tachibana T, Nishikawa T, Hicks GG, Takumi 
T. 2005. The RNA binding protein TLS is translocated to dendritic spines by mGluR5 
activation and regulates spine morphology. Current biology : CB 15: 587-593. 
Fujii R, Takumi T. 2005. TLS facilitates transport of mRNA encoding an actin-stabilizing protein to 
dendritic spines. Journal of cell science 118: 5755-5765. 
73 
 
 References  
Gamsjaeger R, Liew CK, Loughlin FE, Crossley M, Mackay JP. 2007. Sticky fingers: zinc-fingers 
as protein-recognition motifs. Trends in biochemical sciences 32: 63-70. 
Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, Cooch N, Shiekhattar R. 2004. The 
Microprocessor complex mediates the genesis of microRNAs. Nature 432: 235-240. 
Grishin NV. 2001. KH domain: one motif, two folds. Nucleic acids research 29: 638-643. 
Guipaud O, Guillonneau F, Labas V, Praseuth D, Rossier J, Lopez B, Bertrand P. 2006. An in vitro 
enzymatic assay coupled to proteomics analysis reveals a new DNA processing activity for 
Ewing sarcoma and TAF(II)68 proteins. Proteomics 6: 5962-5972. 
Hackl W, Luhrmann R. 1996. Molecular cloning and subcellular localisation of the snRNP-
associated protein 69KD, a structural homologue of the proto-oncoproteins TLS and EWS 
with RNA and DNA-binding properties. Journal of molecular biology 264: 843-851. 
Hafner M, Landgraf P, Ludwig J, Rice A, Ojo T, Lin C, Holoch D, Lim C, Tuschl T. 2008. 
Identification of microRNAs and other small regulatory RNAs using cDNA library 
sequencing. Methods 44: 3-12. 
Hafner M, Landthaler M, Burger L, Khorshid M, Hausser J, Berninger P, Rothballer A, Ascano M, 
Jr., Jungkamp AC, Munschauer M et al. 2010. Transcriptome-wide identification of RNA-
binding protein and microRNA target sites by PAR-CLIP. Cell 141: 129-141. 
Hall TM. 2005. Multiple modes of RNA recognition by zinc finger proteins. Current opinion in 
structural biology 15: 367-373. 
Hallier M, Lerga A, Barnache S, Tavitian A, Moreau-Gachelin F. 1998. The transcription factor Spi-
1/PU.1 interacts with the potential splicing factor TLS. The Journal of biological chemistry 
273: 4838-4842. 
Han TW, Kato M, Xie S, Wu LC, Mirzaei H, Pei J, Chen M, Xie Y, Allen J, Xiao G et al. 2012. 
Cell-free formation of RNA granules: bound RNAs identify features and components of 
cellular assemblies. Cell 149: 768-779. 
Hicks GG, Singh N, Nashabi A, Mai S, Bozek G, Klewes L, Arapovic D, White EK, Koury MJ, 
Oltz EM et al. 2000. Fus deficiency in mice results in defective B-lymphocyte development 
and activation, high levels of chromosomal instability and perinatal death. Nature genetics 
24: 175-179. 
Hoell JI, Larsson E, Runge S, Nusbaum JD, Duggimpudi S, Farazi TA, Hafner M, Borkhardt A, 
Sander C, Tuschl T. 2011. RNA targets of wild-type and mutant FET family proteins. Nature 
structural & molecular biology 18: 1428-1431. 
Hofacker IL. 2004. RNA secondary structure analysis using the Vienna RNA package. Current 
protocols in bioinformatics / editoral board, Andreas D Baxevanis  [et al] Chapter 12: Unit 
12 12. 
Hoffmann A, Roeder RG. 1996. Cloning and characterization of human TAF20/15. Multiple 
interactions suggest a central role in TFIID complex formation. The Journal of biological 
chemistry 271: 18194-18202. 
74 
 
 References  
Huang da W, Sherman BT, Lempicki RA. 2009a. Bioinformatics enrichment tools: paths toward the 
comprehensive functional analysis of large gene lists. Nucleic acids research 37: 1-13. 
-. 2009b. Systematic and integrative analysis of large gene lists using DAVID bioinformatics 
resources. Nature protocols 4: 44-57. 
Huang Y, Steitz JA. 2001. Splicing factors SRp20 and 9G8 promote the nucleocytoplasmic export 
of mRNA. Molecular cell 7: 899-905. 
Ibrahim F, Maragkakis M, Alexiou P, Maronski MA, Dichter MA, Mourelatos Z. 2013. 
Identification of in vivo, conserved, TAF15 RNA binding sites reveals the impact of TAF15 
on the neuronal transcriptome. Cell reports 3: 301-308. 
Ishigaki S, Masuda A, Fujioka Y, Iguchi Y, Katsuno M, Shibata A, Urano F, Sobue G, Ohno K. 
2012. Position-dependent FUS-RNA interactions regulate alternative splicing events and 
transcriptions. Scientific reports 2: 529. 
Ito D, Seki M, Tsunoda Y, Uchiyama H, Suzuki N. 2011. Nuclear transport impairment of 
amyotrophic lateral sclerosis-linked mutations in FUS/TLS. Annals of neurology 69: 152-
162. 
Jia R, Li C, McCoy JP, Deng CX, Zheng ZM. 2010. SRp20 is a proto-oncogene critical for cell 
proliferation and tumor induction and maintenance. International journal of biological 
sciences 6: 806-826. 
Jobert L, Pinzon N, Van Herreweghe E, Jady BE, Guialis A, Kiss T, Tora L. 2009. Human U1 
snRNA forms a new chromatin-associated snRNP with TAF15. EMBO reports 10: 494-500. 
Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ, Gibbs JR, 
Brunetti M, Gronka S, Wuu J et al. 2010. Exome sequencing reveals VCP mutations as a 
cause of familial ALS. Neuron 68: 857-864. 
Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, Bouchard JP, 
Lacomblez L, Pochigaeva K, Salachas F et al. 2008. TARDBP mutations in individuals with 
sporadic and familial amyotrophic lateral sclerosis. Nature genetics 40: 572-574. 
Kahvejian A, Svitkin YV, Sukarieh R, M'Boutchou MN, Sonenberg N. 2005. Mammalian poly(A)-
binding protein is a eukaryotic translation initiation factor, which acts via multiple 
mechanisms. Genes & development 19: 104-113. 
Kato M, Han TW, Xie S, Shi K, Du X, Wu LC, Mirzaei H, Goldsmith EJ, Longgood J, Pei J et al. 
2012. Cell-free formation of RNA granules: low complexity sequence domains form 
dynamic fibers within hydrogels. Cell 149: 753-767. 
Keene JD. 2007. RNA regulons: coordination of post-transcriptional events. Nature reviews 
Genetics 8: 533-543. 
Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC. 2011. 
Amyotrophic lateral sclerosis. Lancet 377: 942-955. 
75 
 
 References  
Kim SH, Shanware NP, Bowler MJ, Tibbetts RS. 2010. Amyotrophic lateral sclerosis-associated 
proteins TDP-43 and FUS/TLS function in a common biochemical complex to co-regulate 
HDAC6 mRNA. The Journal of biological chemistry 285: 34097-34105. 
Kino Y, Washizu C, Aquilanti E, Okuno M, Kurosawa M, Yamada M, Doi H, Nukina N. 2011. 
Intracellular localization and splicing regulation of FUS/TLS are variably affected by 
amyotrophic lateral sclerosis-linked mutations. Nucleic acids research 39: 2781-2798. 
Komarnitsky P, Cho EJ, Buratowski S. 2000. Different phosphorylated forms of RNA polymerase II 
and associated mRNA processing factors during transcription. Genes & development 14: 
2452-2460. 
Krishnamurthy S, He X, Reyes-Reyes M, Moore C, Hampsey M. 2004. Ssu72 Is an RNA 
polymerase II CTD phosphatase. Molecular cell 14: 387-394. 
Kuroda M, Sok J, Webb L, Baechtold H, Urano F, Yin Y, Chung P, de Rooij DG, Akhmedov A, 
Ashley T et al. 2000. Male sterility and enhanced radiation sensitivity in TLS(-/-) mice. The 
EMBO journal 19: 453-462. 
Kwiatkowski TJ, Jr., Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, Davis A, 
Gilchrist J, Kasarskis EJ, Munsat T et al. 2009. Mutations in the FUS/TLS gene on 
chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323: 1205-1208. 
Kwon I, Kato M, Xiang S, Wu L, Theodoropoulos P, Mirzaei H, Han T, Xie S, Corden JL, 
McKnight SL. 2013. Phosphorylation-regulated binding of RNA polymerase II to fibrous 
polymers of low-complexity domains. Cell 155: 1049-1060. 
Lagier-Tourenne C, Polymenidou M, Hutt KR, Vu AQ, Baughn M, Huelga SC, Clutario KM, Ling 
SC, Liang TY, Mazur C et al. 2012. Divergent roles of ALS-linked proteins FUS/TLS and 
TDP-43 intersect in processing long pre-mRNAs. Nature neuroscience 15: 1488-1497. 
Lebedeva S, Jens M, Theil K, Schwanhausser B, Selbach M, Landthaler M, Rajewsky N. 2011. 
Transcriptome-wide analysis of regulatory interactions of the RNA-binding protein HuR. 
Mol Cell 43: 340-352. 
Lee J, Rhee BK, Bae GY, Han YM, Kim J. 2005. Stimulation of Oct-4 activity by Ewing's sarcoma 
protein. Stem cells 23: 738-751. 
Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S et al. 2003. The 
nuclear RNase III Drosha initiates microRNA processing. Nature 425: 415-419. 
Leemann-Zakaryan RP, Pahlich S, Grossenbacher D, Gehring H. 2011. Tyrosine Phosphorylation in 
the C-Terminal Nuclear Localization and Retention Signal (C-NLS) of the EWS Protein. 
Sarcoma 2011: 218483. 
Lerga A, Hallier M, Delva L, Orvain C, Gallais I, Marie J, Moreau-Gachelin F. 2001. Identification 
of an RNA binding specificity for the potential splicing factor TLS. The Journal of 
biological chemistry 276: 6807-6816. 
76 
 
 References  
Lewis HA, Chen H, Edo C, Buckanovich RJ, Yang YY, Musunuru K, Zhong R, Darnell RB, Burley 
SK. 1999. Crystal structures of Nova-1 and Nova-2 K-homology RNA-binding domains. 
Structure 7: 191-203. 
Li H, Watford W, Li C, Parmelee A, Bryant MA, Deng C, O'Shea J, Lee SB. 2007. Ewing sarcoma 
gene EWS is essential for meiosis and B lymphocyte development. The Journal of clinical 
investigation 117: 1314-1323. 
Lin CL, Bristol LA, Jin L, Dykes-Hoberg M, Crawford T, Clawson L, Rothstein JD. 1998. Aberrant 
RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate 
transporter, in amyotrophic lateral sclerosis. Neuron 20: 589-602. 
Ling SC, Albuquerque CP, Han JS, Lagier-Tourenne C, Tokunaga S, Zhou H, Cleveland DW. 2010. 
ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes 
with FUS/TLS. Proceedings of the National Academy of Sciences of the United States of 
America 107: 13318-13323. 
Loughlin FE, Mansfield RE, Vaz PM, McGrath AP, Setiyaputra S, Gamsjaeger R, Chen ES, Morris 
BJ, Guss JM, Mackay JP. 2009. The zinc fingers of the SR-like protein ZRANB2 are single-
stranded RNA-binding domains that recognize 5' splice site-like sequences. Proceedings of 
the National Academy of Sciences of the United States of America 106: 5581-5586. 
Lu Z, Xu S, Joazeiro C, Cobb MH, Hunter T. 2002. The PHD domain of MEKK1 acts as an E3 
ubiquitin ligase and mediates ubiquitination and degradation of ERK1/2. Molecular cell 9: 
945-956. 
Lunde BM, Moore C, Varani G. 2007. RNA-binding proteins: modular design for efficient function. 
Nature reviews Molecular cell biology 8: 479-490. 
Marko M, Vlassis A, Guialis A, Leichter M. 2012. Domains involved in TAF15 subcellular 
localisation: dependence on cell type and ongoing transcription. Gene 506: 331-338. 
Martini A, La Starza R, Janssen H, Bilhou-Nabera C, Corveleyn A, Somers R, Aventin A, Foa R, 
Hagemeijer A, Mecucci C et al. 2002. Recurrent rearrangement of the Ewing's sarcoma 
gene, EWSR1, or its homologue, TAF15, with the transcription factor CIZ/NMP4 in acute 
leukemia. Cancer research 62: 5408-5412. 
Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, Kinoshita Y, Kamada M, Nodera H, 
Suzuki H et al. 2010. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 465: 
223-226. 
Matthews JM, Sunde M. 2002. Zinc fingers--folds for many occasions. IUBMB life 54: 351-355. 
Mazza C, Segref A, Mattaj IW, Cusack S. 2002. Large-scale induced fit recognition of an 
m(7)GpppG cap analogue by the human nuclear cap-binding complex. The EMBO journal 
21: 5548-5557. 
Meissner M, Lopato S, Gotzmann J, Sauermann G, Barta A. 2003. Proto-oncoprotein TLS/FUS is 
associated to the nuclear matrix and complexed with splicing factors PTB, SRm160, and SR 
proteins. Experimental cell research 283: 184-195. 
77 
 
 References  
Meyer H, Bug M, Bremer S. 2012. Emerging functions of the VCP/p97 AAA-ATPase in the 
ubiquitin system. Nature cell biology 14: 117-123. 
Michelitsch MD, Weissman JS. 2000. A census of glutamine/asparagine-rich regions: implications 
for their conserved function and the prediction of novel prions. Proceedings of the National 
Academy of Sciences of the United States of America 97: 11910-11915. 
Miller J, McLachlan AD, Klug A. 1985. Repetitive zinc-binding domains in the protein 
transcription factor IIIA from Xenopus oocytes. The EMBO journal 4: 1609-1614. 
Montes M, Becerra S, Sanchez-Alvarez M, Sune C. 2012. Functional coupling of transcription and 
splicing. Gene 501: 104-117. 
Morlando M, Dini Modigliani S, Torrelli G, Rosa A, Di Carlo V, Caffarelli E, Bozzoni I. 2012. FUS 
stimulates microRNA biogenesis by facilitating co-transcriptional Drosha recruitment. The 
EMBO journal 31: 4502-4510. 
Morris DP, Michelotti GA, Schwinn DA. 2005. Evidence that phosphorylation of the RNA 
polymerase II carboxyl-terminal repeats is similar in yeast and humans. The Journal of 
biological chemistry 280: 31368-31377. 
Morris KV, Santoso S, Turner AM, Pastori C, Hawkins PG. 2008. Bidirectional transcription directs 
both transcriptional gene activation and suppression in human cells. PLoS genetics 4: 
e1000258. 
Moscat J, Diaz-Meco MT. 2012. p62: a versatile multitasker takes on cancer. Trends in biochemical 
sciences 37: 230-236. 
Neumann M, Bentmann E, Dormann D, Jawaid A, DeJesus-Hernandez M, Ansorge O, Roeber S, 
Kretzschmar HA, Munoz DG, Kusaka H et al. 2011. FET proteins TAF15 and EWS are 
selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral 
sclerosis with FUS mutations. Brain : a journal of neurology 134: 2595-2609. 
Neumann M, Rademakers R, Roeber S, Baker M, Kretzschmar HA, Mackenzie IR. 2009. A new 
subtype of frontotemporal lobar degeneration with FUS pathology. Brain 132: 2922-2931. 
Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, 
Grossman M, Clark CM et al. 2006. Ubiquitinated TDP-43 in frontotemporal lobar 
degeneration and amyotrophic lateral sclerosis. Science 314: 130-133. 
Nguyen CD, Mansfield RE, Leung W, Vaz PM, Loughlin FE, Grant RP, Mackay JP. 2011. 
Characterization of a family of RanBP2-type zinc fingers that can recognize single-stranded 
RNA. Journal of molecular biology 407: 273-283. 
Ohno T, Ouchida M, Lee L, Gatalica Z, Rao VN, Reddy ES. 1994. The EWS gene, involved in 
Ewing family of tumors, malignant melanoma of soft parts and desmoplastic small round 
cell tumors, codes for an RNA binding protein with novel regulatory domains. Oncogene 9: 
3087-3097. 
78 
 
 References  
Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, Mann M. 2002. Stable 
isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to 
expression proteomics. Molecular & cellular proteomics : MCP 1: 376-386. 
Oubridge C, Ito N, Evans PR, Teo CH, Nagai K. 1994. Crystal structure at 1.92 A resolution of the 
RNA-binding domain of the U1A spliceosomal protein complexed with an RNA hairpin. 
Nature 372: 432-438. 
Paronetto MP, Minana B, Valcarcel J. 2011. The Ewing sarcoma protein regulates DNA damage-
induced alternative splicing. Molecular cell 43: 353-368. 
Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, Ling SC, Sun E, 
Wancewicz E, Mazur C et al. 2011. Long pre-mRNA depletion and RNA missplicing 
contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci 14: 459-468. 
Preker P, Nielsen J, Kammler S, Lykke-Andersen S, Christensen MS, Mapendano CK, Schierup 
MH, Jensen TH. 2008. RNA exosome depletion reveals transcription upstream of active 
human promoters. Science 322: 1851-1854. 
Price SR, Evans PR, Nagai K. 1998. Crystal structure of the spliceosomal U2B"-U2A' protein 
complex bound to a fragment of U2 small nuclear RNA. Nature 394: 645-650. 
Proudfoot NJ, Furger A, Dye MJ. 2002. Integrating mRNA processing with transcription. Cell 108: 
501-512. 
Pruitt KD, Tatusova T, Maglott DR. 2005. NCBI Reference Sequence (RefSeq): a curated non-
redundant sequence database of genomes, transcripts and proteins. Nucleic acids research 
33: D501-504. 
Rabbitts TH, Forster A, Larson R, Nathan P. 1993. Fusion of the dominant negative transcription 
regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. 
Nature genetics 4: 175-180. 
Rabin SJ, Kim JM, Baughn M, Libby RT, Kim YJ, Fan Y, Libby RT, La Spada A, Stone B, Ravits J. 
2010. Sporadic ALS has compartment-specific aberrant exon splicing and altered cell-matrix 
adhesion biology. Human molecular genetics 19: 313-328. 
Rappsilber J, Ryder U, Lamond AI, Mann M. 2002. Large-scale proteomic analysis of the human 
spliceosome. Genome research 12: 1231-1245. 
Ray D, Kazan H, Cook KB, Weirauch MT, Najafabadi HS, Li X, Gueroussov S, Albu M, Zheng H, 
Yang A et al. 2013. A compendium of RNA-binding motifs for decoding gene regulation. 
Nature 499: 172-177. 
Reed R. 1989. The organization of 3' splice-site sequences in mammalian introns. Genes & 
development 3: 2113-2123. 
Rogelj B, Easton LE, Bogu GK, Stanton LW, Rot G, Curk T, Zupan B, Sugimoto Y, Modic M, 
Haberman N et al. 2012. Widespread binding of FUS along nascent RNA regulates 
alternative splicing in the brain. Scientific reports 2: 603. 
79 
 
 References  
Rubino E, Rainero I, Chio A, Rogaeva E, Galimberti D, Fenoglio P, Grinberg Y, Isaia G, Calvo A, 
Gentile S et al. 2012. SQSTM1 mutations in frontotemporal lobar degeneration and 
amyotrophic lateral sclerosis. Neurology 79: 1556-1562. 
Sasagawa K, Matsudo Y, Kang M, Fujimura L, Iitsuka Y, Okada S, Ochiai T, Tokuhisa T, Hatano M. 
2002. Identification of Nd1, a novel murine kelch family protein, involved in stabilization of 
actin filaments. The Journal of biological chemistry 277: 44140-44146. 
Schwanhausser B, Gossen M, Dittmar G, Selbach M. 2009. Global analysis of cellular protein 
translation by pulsed SILAC. Proteomics 9: 205-209. 
Schwartz JC, Ebmeier CC, Podell ER, Heimiller J, Taatjes DJ, Cech TR. 2012. FUS binds the CTD 
of RNA polymerase II and regulates its phosphorylation at Ser2. Genes & development 26: 
2690-2695. 
Schwartz JC, Wang X, Podell ER, Cech TR. 2013. RNA Seeds Higher-Order Assembly of FUS 
Protein. Cell reports 5: 918-925. 
Shelkovnikova TA, Peters OM, Deykin AV, Connor-Robson N, Robinson H, Ustyugov AA, 
Bachurin SO, Ermolkevich TG, Goldman IL, Sadchikova ER et al. 2013. Fused in sarcoma 
(FUS) protein lacking nuclear localization signal (NLS) and major RNA binding motifs 
triggers proteinopathy and severe motor phenotype in transgenic mice. The Journal of 
biological chemistry 288: 25266-25274. 
Shiohama A, Sasaki T, Noda S, Minoshima S, Shimizu N. 2007. Nucleolar localization of DGCR8 
and identification of eleven DGCR8-associated proteins. Experimental cell research 313: 
4196-4207. 
Sohn EJ, Park J, Kang SI, Wu YP. 2012. Accumulation of pre-let-7g and downregulation of mature 
let-7g with the depletion of EWS. Biochemical and biophysical research communications 
426: 89-93. 
Spahn L, Petermann R, Siligan C, Schmid JA, Aryee DN, Kovar H. 2002. Interaction of the EWS 
NH2 terminus with BARD1 links the Ewing's sarcoma gene to a common tumor suppressor 
pathway. Cancer research 62: 4583-4587. 
Spitzer JI, Ugras S, Runge S, Decarolis P, Antonescu C, Tuschl T, Singer S. 2011. mRNA and 
protein levels of FUS, EWSR1, and TAF15 are upregulated in liposarcoma. Genes, 
chromosomes & cancer 50: 338-347. 
Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams 
KL, Buratti E et al. 2008. TDP-43 mutations in familial and sporadic amyotrophic lateral 
sclerosis. Science 319: 1668-1672. 
Stefl R, Oberstrass FC, Hood JL, Jourdan M, Zimmermann M, Skrisovska L, Maris C, Peng L, Hofr 
C, Emeson RB et al. 2010. The solution structure of the ADAR2 dsRBM-RNA complex 
reveals a sequence-specific readout of the minor groove. Cell 143: 225-237. 
Stefl R, Skrisovska L, Allain FH. 2005. RNA sequence- and shape-dependent recognition by 
proteins in the ribonucleoprotein particle. EMBO reports 6: 33-38. 
80 
 
 References  
Takahama K, Takada A, Tada S, Shimizu M, Sayama K, Kurokawa R, Oyoshi T. 2013. Regulation 
of telomere length by G-quadruplex telomere DNA- and TERRA-binding protein TLS/FUS. 
Chemistry & biology 20: 341-350. 
Tan AY, Manley JL. 2009. The TET family of proteins: functions and roles in disease. Journal of 
molecular cell biology 1: 82-92. 
-. 2010. TLS inhibits RNA polymerase III transcription. Molecular and cellular biology 30: 186-
196. 
Teyssou E, Takeda T, Lebon V, Boillee S, Doukoure B, Bataillon G, Sazdovitch V, Cazeneuve C, 
Meininger V, LeGuern E et al. 2013. Mutations in SQSTM1 encoding p62 in amyotrophic 
lateral sclerosis: genetics and neuropathology. Acta neuropathologica 125: 511-522. 
Thomas GR, Latchman DS. 2002. The pro-oncoprotein EWS (Ewing's Sarcoma protein) interacts 
with the Brn-3a POU transcription factor and inhibits its ability to activate transcription. 
Cancer biology & therapy 1: 428-432. 
Ticozzi N, Vance C, Leclerc AL, Keagle P, Glass JD, McKenna-Yasek D, Sapp PC, Silani V, Bosco 
DA, Shaw CE et al. 2011. Mutational analysis reveals the FUS homolog TAF15 as a 
candidate gene for familial amyotrophic lateral sclerosis. American journal of medical 
genetics Part B, Neuropsychiatric genetics : the official publication of the International 
Society of Psychiatric Genetics 156B: 285-290. 
Tollervey JR, Curk T, Rogelj B, Briese M, Cereda M, Kayikci M, Konig J, Hortobagyi T, Nishimura 
AL, Zupunski V et al. 2011. Characterizing the RNA targets and position-dependent splicing 
regulation by TDP-43. Nat Neurosci 14: 452-458. 
Trapnell C, Pachter L, Salzberg SL. 2009. TopHat: discovering splice junctions with RNA-Seq. 
Bioinformatics 25: 1105-1111. 
Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ, 
Pachter L. 2010. Transcript assembly and quantification by RNA-Seq reveals unannotated 
transcripts and isoform switching during cell differentiation. Nature biotechnology 28: 511-
515. 
Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J, Hu X, Smith B, Ruddy 
D, Wright P et al. 2009. Mutations in FUS, an RNA processing protein, cause familial 
amyotrophic lateral sclerosis type 6. Science 323: 1208-1211. 
Venkitaraman AR. 2001. Functions of BRCA1 and BRCA2 in the biological response to DNA 
damage. Journal of cell science 114: 3591-3598. 
Wang X, Arai S, Song X, Reichart D, Du K, Pascual G, Tempst P, Rosenfeld MG, Glass CK, 
Kurokawa R. 2008. Induced ncRNAs allosterically modify RNA-binding proteins in cis to 
inhibit transcription. Nature 454: 126-130. 
Workman JL, Roeder RG. 1987. Binding of transcription factor TFIID to the major late promoter 
during in vitro nucleosome assembly potentiates subsequent initiation by RNA polymerase 
II. Cell 51: 613-622. 
81 
 
 References  
Wu S, Green MR. 1997. Identification of a human protein that recognizes the 3' splice site during 
the second step of pre-mRNA splicing. The EMBO journal 16: 4421-4432. 
Xiao S, Sanelli T, Dib S, Sheps D, Findlater J, Bilbao J, Keith J, Zinman L, Rogaeva E, Robertson 
J. 2011. RNA targets of TDP-43 identified by UV-CLIP are deregulated in ALS. Molecular 
and cellular neurosciences 47: 167-180. 
Yang L, Chansky HA, Hickstein DD. 2000. EWS.Fli-1 fusion protein interacts with 
hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-
mediated RNA splicing. The Journal of biological chemistry 275: 37612-37618. 
Yang L, Embree LJ, Tsai S, Hickstein DD. 1998. Oncoprotein TLS interacts with serine-arginine 
proteins involved in RNA splicing. The Journal of biological chemistry 273: 27761-27764. 
Yeom KH, Lee Y, Han J, Suh MR, Kim VN. 2006. Characterization of DGCR8/Pasha, the essential 
cofactor for Drosha in primary miRNA processing. Nucleic acids research 34: 4622-4629. 
Zakaryan RP, Gehring H. 2006. Identification and characterization of the nuclear 
localization/retention signal in the EWS proto-oncoprotein. Journal of molecular biology 
363: 27-38. 
Zinszner H, Albalat R, Ron D. 1994. A novel effector domain from the RNA-binding protein TLS 
or EWS is required for oncogenic transformation by CHOP. Genes & development 8: 2513-
2526. 
Zinszner H, Sok J, Immanuel D, Yin Y, Ron D. 1997. TLS (FUS) binds RNA in vivo and engages in 
nucleo-cytoplasmic shuttling. Journal of cell science 110 ( Pt 15): 1741-1750. 
Zucman J, Melot T, Desmaze C, Ghysdael J, Plougastel B, Peter M, Zucker JM, Triche TJ, Sheer D, 
Turc-Carel C et al. 1993. Combinatorial generation of variable fusion proteins in the Ewing 
family of tumours. The EMBO journal 12: 4481-4487. 
 
82 
 
 List of abbreviations  
List of abbreviations 
4SU 4-thiouridine 
6SG 6-thioguanosine 
AE amplification efficiency 
ALS amyotrophic lateral sclerosis 
ATP adenosine triphosphate 
BARD1 BRCA1-associated ring finger domain protein 1 
bp base pairs 
BRCA1 breast cancer 1 
BWA Burrows-Wheeler Alignment tool 
C9orf72 chromosome 9 open reading frame 72 
CBP CREB-binding protein 
CCND1 cyclin D1 
CCR crosslink centered region 
CDF cumulative distribution function 
CDK1 cyclin-dependent kinase 1 
CDKN1A cyclin-dependent kinase inhibitor 1A 
cDNA complementary DNA 
CDS coding sequence 
ChIP chromatin immunoprecipitation 
CHOP CCAAT/enhancer-binding homologous protein 
CSNK1D casein kinase 1 delta 
Ct cycle treshold 
CTD carboxy terminal domain 
83 
 
 List of abbreviations  
C-terminus carboxy-terminus 
DGCR8 DiGeorge syndrome critical region 8 
DMEM Dulbecco’s modified Eagle’s medium 
DNA deoxyribonucleic acid 
ds double-stranded 
dsRBM double-stranded RNA-binding motif 
EAA2 excitatory amino acid transporter 2 
EDTA Ethylenediaminetetraacetic acid 
EMSA electrophoretic mobility shift assay 
ENAH enabled homolog 
ERG v-ets avian erythroblastosis virus E26 oncogene homolog 
EWSR1 EWS RNA-binding protein 1 
FBS fetal bovine serum 
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qPCR quantitative polymerase chain reaction 
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RanBP2 RAN binding protein 2 
RBP RNA-binding protein 
RefSeq reference sequence 
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RNAi RNA interference 
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RT room temperature 
SC35 splicing component, 35 kDa 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
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siRNA small interfering RNA 
snRNA small nuclear RNA 
SOD1 superoxide dismutase 1 
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ss single-stranded 
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SYGQ-domain serine-tyrosine-glycine-glutamine-rich domain 
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TFIID transcription factor II D 
THAP6 THAP domain containing 6 
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Normalized small RNA-seq reads upon knockdown relative to mock 
miRNA miRNA precursor 
FUS 
siRNA1 
FUS 
siRNA2 
EWSR1 
siRNA1 
EWSR1 
siRNA2 
TAF15 
siRNA1 
TAF15 
siRNA2 
Triple 
KD 
hsa-miR-103a hsa-mir-103a-2 1,34 1,31 0,66 0,82 0,08 0,88 0,92 
hsa-miR-103a hsa-mir-103a-1 1,34 1,31 0,66 0,82 0,08 0,88 0,92 
hsa-miR-16 hsa-mir-16-1 0,58 0,64 1,86 0,57 0,43 0,77 1,19 
hsa-miR-16 hsa-mir-16-2 0,58 0,64 1,86 0,57 0,43 0,76 1,19 
hsa-let-7a hsa-let-7a-2 1,05 1,68 0,95 1,97 1,52 1,63 0,75 
hsa-let-7a hsa-let-7a-3 1,05 1,68 0,95 1,98 1,50 1,64 0,75 
hsa-let-7a hsa-let-7a-1 1,05 1,68 0,95 1,98 1,50 1,64 0,75 
hsa-miR-92a hsa-mir-92a-1 1,67 1,62 1,45 2,57 7,46 1,75 0,54 
hsa-miR-17 hsa-mir-17 0,92 1,80 1,24 2,39 0,52 2,38 0,53 
hsa-miR-92a hsa-mir-92a-2 1,71 1,65 1,45 2,63 7,19 1,75 0,53 
hsa-miR-320a hsa-mir-320a 1,60 0,89 0,52 0,89 0,66 0,95 2,28 
hsa-miR-148a hsa-mir-148a 2,63 1,66 1,18 1,27 0,42 1,43 0,71 
hsa-miR-7 hsa-mir-7-1 0,30 0,23 0,32 0,29 0,13 0,36 1,92 
hsa-miR-26a hsa-mir-26a-2 0,91 1,08 1,04 0,89 0,55 0,85 1,55 
hsa-miR-26a hsa-mir-26a-1 0,91 1,08 1,04 0,89 0,55 0,85 1,55 
hsa-miR-7 hsa-mir-7-2 0,29 0,22 0,31 0,29 0,11 0,36 1,98 
hsa-miR-7 hsa-mir-7-3 0,29 0,22 0,31 0,29 0,11 0,36 1,98 
hsa-miR-10a hsa-mir-10a 1,08 0,95 1,92 0,88 1,36 1,49 1,19 
hsa-miR-93 hsa-mir-93 1,10 1,03 1,66 1,64 0,41 1,02 0,56 
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hsa-miR-378 hsa-mir-378 4,33 1,85 1,38 1,78 0,97 1,64 0,48 
hsa-miR-15a hsa-mir-15a 0,31 0,48 4,32 0,83 0,34 0,62 0,42 
hsa-miR-26b hsa-mir-26b 1,60 1,40 1,26 1,28 0,53 1,16 0,62 
hsa-miR-10b hsa-mir-10b 2,43 1,73 1,26 1,20 6,42 1,72 0,53 
hsa-miR-148b hsa-mir-148b 2,50 1,36 0,52 1,21 0,51 0,99 0,73 
hsa-miR-15b hsa-mir-15b 0,31 0,54 0,59 0,69 0,26 0,79 1,61 
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